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Abstract 
Traditionally the two major classes of drugs, small molecules and biologics, have been 
extensively used in drug discovery. However, it is difficult to inhibit protein-protein interactions 
with small molecules, and targets of biologics are limited to extracellular proteins. Considering 
such limitations, there has been a call for a new therapeutic modality to target ‘undruggable’ 
proteins. Structurally-stabilized peptide therapeutics has emerged as a new class that could 
overcome the limitations of the previously established drug classes while retaining their benefits. 
Among several strategies that have been employed to constrain the conformation of peptides to 
enhance their pharmacological properties, the all-hydrocarbon stapling system has been 
particularly successful. This system combines the helix-stabilizing effects of alpha methylation 
with peptide macrocyclization, which confers improvement not only in helix stabilization but 
also in protease resistance and cell permeability. The first part of my dissertation focuses on 
exploring this system further by shortening the established hydrocarbon bridge length as well as 
moving the position of the olefin along the cross-link, and looking at the effects of these 
attributes on the helical propensity of the peptides by circular dichroism. 
	  	   iv	  
In cases where there is no structural information or obvious binding partner that has an alpha-
helical component that could be used for rational design of a stapled peptide inhibitor, screening 
a naïve library of stabilized scaffolds using yeast cell-surface display would be an alternative 
starting point. Oncogenic K-Ras is one such case; the structures of Ras with its effectors have 
shown that they interact with Ras via beta-sheet complementation. The second part of my 
dissertation will describe efforts to develop peptide inhibitors that target Ras by using screening 
and directed evolution of libraries of an avian pancreatic polypeptide-based scaffold by yeast 
cell-surface display. We have identified lead peptides that disrupt the binding of effectors to Ras, 
and the structures of these peptides bound to Ras have been solved and analyzed, leading us to 
improve the lead peptides further by rational design.  
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A step toward achieving peptide based therapeutics 
Traditionally, small molecules have been used heavily as drug modalities. They can be optimized 
to pass through membranes, so there isn’t much geographic limitation. However, with their small 
sizes, they have limited surface area. According to Lipinski’s rule of five for attaining oral 
bioavailability, the general guideline of the molecular weight cut off for small molecules has 
been limited to 500.  Unfortunately, as molecular weight and therefore compound size is 
restricted, the pool of the possible targets also becomes smaller. Empirically small molecules 
work by binding to hydrophobic pockets of the targets, which confer high affinity and 
specificity. Therefore the use of small molecules as therapeutics is limited to target proteins that 
can accommodate them by having hydrophobic pockets. To make the problems worse, 
hydrophobic pockets that are already in the proteins are there for a reason; they are already 
optimized for binding to cofactors or substrates against which small molecules would have to 
compete. In many cases, protein-protein interactions (PPIs) have large contact area with an 
extensive interface. However with the area being a mostly flat surface, there is no hydrophobic 
pocket that a small molecule can target. On the other hand, for biologics, they have unlimited 
targeting power regardless of the protein surface. However, such large molecules are limited in 
that they are not able to penetrate cell membranes; they could only be used to target extracellular 
proteins.  
 
It has been estimated that small molecules can be used for only 10 % of prospective target 
proteins, and biologics for another 10 % 1 . Since there might be some overlap between those 
two, more than 80% of targets are thought to be “undruggable”. This calls for a new therapeutic 
modality that can overcome the limitations of small molecules and biologics while retaining their 
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benefits. This is why the idea of a cell-penetrating ‘mini-protein’ is appealing. In a given PPI, 
there is generally an interaction domain in the protein that is crucial for the binding, while the 
remaining part of the protein is there to support the overall structure. Therefore, the idea here is 
to mimic the hot-spot binding region to disrupt the target PPI. However, in reality it is not as 
simple as just stripping down the protein to its business end. When the peptide is taken out from 
its context, it tends to lose its structure since there is an entropy cost of going from disordered to 
ordered structure. The problems coming from peptides being unfolded are that they show low 
binding affinities to targets, get rapidly degraded by proteases due to their exposed amide bonds, 
and have poor cell permeability due in part to the partial charges that derive from amide bonds. 
Therefore, there is a need to constrain the conformation so that the peptide can retain its active 
structure.  
 
In order to preserve the recognition ability of the secondary structure by retaining its ordered 
structure, macrocyclic ring formation has long been established as a particularly effective 
strategy for the conformational reinforcement of peptides 2,3  4 . Many types of bond-forming 
reactions have been used to close macrocyclic rings in peptides, but the powerful ring-forming 
ability of ring closing metathesis (RCM) 5  has proven particularly useful in generating 
conformationally stabilized peptides. The olefin metathesis here refers to metal-catalyzed 
redistribution of carbon-carbon double bonds 6 . Following the groundbreaking work of Miller 
and Grubbs 7  on the conformational stabilization of beta-turn structures via RCM, this reaction 
has been employed in ring-formation processes leading to a variety of enforced peptide 
conformations 8–12 . Peptide macrocyclization is among the most effective strategies for 
promoting the formation of helical structures in peptides 13 ; here again, RCM-based systems 
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have demonstrated value in stabilizing both 310- 8,9  and alpha-helical 11 conformations. Although 
both these helical forms are well represented in protein structures, alpha-helices are considerably 
more common and of much greater average length than 310-helices. Considering that alpha-
helices are more prevalent than any other single motif in mediating protein-macromolecule 
interactions 13 , this particular helical form has attracted recent attention as one potential avenue 
toward generating next-generation therapeutics. Thus, there have been numerous attempts in 
trying to stabilize the α-helix, such as employing salt bridges 14 , lactams 15  and disulfide bridges 
16 . 
 
Of the dozen or so systems reported to stabilize alpha-helical structures in peptides, one has 
gained particular interest owing to its superior helix-stabilizing power and unprecedented ability 
to confer robust cell penetration upon the peptide bearing it. This system, the all-hydrocarbon 
‘staple’  10,17 , is the first to combine the helix-stabilizing effects of macrocyclization of the 
peptides 8 , with the equally powerful effects of alpha-methylation, first described by Karle et al. 
18 .  
 
One of the most widely employed staples, Si,i+4S(8), is introduced by incorporation of two units 
of the alpha-methyl, alpha-alkenyl amino acid S5 (The unnatural amino acids are denoted in the 
form of Xy, where X indicates the stereochemistry of the alpha-carbon and Y the number of 
carbons in the alkene chain) into a peptide at the relative positions of i and i+4, followed by 
RCM to close an 8-carbon all-hydrocarbon macrocyclic ring spanning one turn of a helix. 
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In a spate of published studies, this and a closely related i,i+7 system, which covers two turns of 
an alpha-helical backbone, have been shown to provide significant improvements in alpha-
helical character, target-binding affinity, proteolytic resistance, and serum half-life. Most 
distinctively, stapling has been found frequently to confer robust cell penetration by an active 
mechanism involving endocytic vesicle formation and trafficking 19–22 . This hydrocarbon 
stapling system has been successfully deployed by our laboratory and others against a variety of 
biological targets and stands apart from all other helix-stabilization systems as the sole example 
that has been shown effective in animal models of a human disease driven by an intracellular 
target 23–28 .  
 
The ability of stapled peptides to access intracellular targets that engage in protein-protein 
interactions, targets typically considered intractable, underlies the tremendous interest in these 
agents as potential next-generation therapeutics having a distinctive and uniquely powerful 
targeting range. The first part of my thesis focuses on the extension of these efforts by exploring 
staples having shorter linker lengths and/or alternative positions of the olefin along the 
hydrocarbon cross-link. The content from the chapter within this part that describes the 6-carbon 
i, i+3 stapled peptides has been published : Shim, S. Y., Kim, Y.-W. W. & Verdine, G. L. A new 
i, i+3 peptide stapling system for α-helix stabilization. Chem Biol Drug Des 82, 635–42 (2013). 
 
High-resolution structures of PPIs are important in employing and rationally designing stapled 
peptides. However, there are cases where there are no obvious binding partners that have an 
alpha-helical component that could be used as a starting point for this approach. For example, the 
oncogenic K-Ras protein does not have any known alpha-helical interactor; a crystal structure of 
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the binding face of Ras and Raf shows that they are interacting via beta sheet complementation. 
In such cases, we cannot rationally design a helical structure as an inhibitor. Instead, we have 
approached the problem by first screening a yeast cell surface display library of a stabilized 
scaffold using directed evolution, and then improving the affinity of the lead peptide further by 
rational design based on the structural analysis, which will be described in the second part of my 
thesis. This project was collaborated with Dr. John McGee and Dr. Matt Lee; Dr. John McGee 
designed the libraries for yeast display system and did screening for the heterodimer peptide, as 
well as most biochemical experiments to determine the binding of the hit peptides to Ras. With 
the hit peptides I expressed from the bacterial expression, Dr. Matt Lee did crystallization 
experiment and solved the structures for the RDA 1 peptides bound Ras as well as RDA 2 
peptides bound Ras. 
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Part I. Analysis of the effect of olefin position and linker length in 
hydrocarbon stapled peptides 
Chapter 1. Introduction 
It has been determined in the published studies from our lab that the extent of alpha-helix 
stabilization and nucleation by staples that encompass a single helical turn (i, i+4 and i, i+3) and 
that possess an 8-carbon macrocyclic bridge (i.e., formed using a combination of S5 and R5) is 
highly dependent both on the stereochemistry of the alpha-methyl, alpha-alkenyl amino acids 
used to form the staple and also on the position of the staple within a given peptide sequence. 
Whereas two units of S5 gave the most helix-stabilizing staple in the i, i+4 configuration 
(Si,i+4S(8) staple), the i, i+3 configuration was most optimal with an N-terminal R5 residue and a 
C-terminal S5 residue (Ri,i+3S(8) staple) 29,30 .  
 
Although the conventional 8-atom i, i+4 system continues to enjoy considerable success and 
scope of applicability 17,23,24,28,31 , we have occasionally observed troublesome aggregation in 
peptides bearing this staple and have reasoned that this problem might be mitigated by 
diminishing the hydrocarbon content of the macrocyclic bridge. Additional motivation for a 
broader investigation of variant hydrocarbon staples comes from several recent studies in which 
the hydrocarbon portion of the staple has been found to engage the target directly through 
hydrocarbon contacts with residues lining the peptide-binding pocket of the target 32,33  27 . These 
findings have suggested that in certain instances, the macrocyclic bridge should itself be the 
subject of structure-activity investigations to maximize target-binding affinity.  
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In the i, i+4 system, it has been previously shown that contraction of the hydrocarbon bridge 
from 8 to 6 atoms leads to a complete failure of RCM, such that helicity in the product could 
never be assessed 10 . However, we decided to revisit and further investigate the effects on alpha-
helicity of having short linkers of 6 to 7 carbons in the i, i+4 system, this time trying high 
temperature and/or different catalysts to see if that would help overcome the energy barrier for 
RCM and yield stapled products. This effort is described in chapter 2, where we learned not only 
that it is possible to yield stapled products with the 7-carbon bridge, but also that it retains alpha 
helicity comparable to that of the 8-carbon bridge. 
 
In the case of the i, i+3 staple configuration, preliminary modeling studies suggested that a 6-
atom hydrocarbon bridge bearing a cis-olefin could be accommodated without significant 
disruption of the helix. (P.S. Kutchukian and G.L. Verdine, unpublished results). The studies in 
chapter 3 were therefore undertaken to explore the synthetic feasibility and biophysical effects of 
contracting the hydrocarbon bridge in i, i+3 staple peptides from 8 atoms to 6. In chapter 4, we 
describe studies to reduce the length of the bridge to 4 atoms, which was found to stabilize 
another secondary structure, the 310-helix.  
 
The overall scheme of the shorter linker stapled peptides examined in this thesis is shown below. 
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Scheme 1. The i, i+3 and i, i+4 shorter linker hydrocarbon stapled peptides examined in this study.  
 
Chapter 2. Shorter hydrocarbon bridge in i,i+4 stapled peptides  
 
It has been shown that for i, i+4 stapled peptides, an 8-atom hydrocarbon bridge results in the 
most alpha-helix stabilization. When the hydrocarbon linker was contracted down to a 6-atom 
bridge, it was reported that the metathesis reaction failed 10 . Here, we decided to revisit the 
possibility of obtaining a shorter hydrocarbon bridge for the i, i+4 stapling system that still 
stabilizes alpha-helicity, in the hope of adding another possible linker to our stapling system tool 
box.  
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Table 1. Shorter linker i, i+4 stapled peptide sequences. The sequences are N-terminally acetylated 
and C-terminally amidated. 
 
 
We utilized the C-peptide sequence of RNaseA 34  for the purpose of direct comparison with 
previous studies, since how readily the stapling system works and the resulting helical content is 
sequence dependent due to factors such as the tendency of the original sequence to form an 
alpha-helix 22 (Table 1). The RNaseA sequence has been used in a number of studies due to its 
partial helicity in water, which enables us to observe either an increase or decrease in helicity 
that comes from its modification. Along with the wild type sequence, either S3 or S5 unnatural 
amino acids were incorporated in i, i+4 phasing to make all possible pairs (S3-S3, S3-S5, S5-S3 or 
S5-S5). Although the typical reaction conditions from the literature would be to use Grubbs first 
generation catalyst (GI catalyst) at room temperature 19 , in order to maximize conversion to the 
stapled products we also tested elevated temperatures up to 65 oC and different catalysts, namely 
Grubbs second generation catalyst (GII catalyst), Grubbs third generation catalyst (GIII catalyst) 
and Hoveyda-Grubbs second generation catalyst (HGII catalyst) at room temperature (Figure 1). 
  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
A E W A E T A A A K F L A A H A
B E W A E T A A S5 K F L S5 A H A
C E W A E T A A S3 K F L S3 A H A
D E W A E T A A S3 K F L S5 A H A
E E W A E T A A S5 K F L S3 A H A
RNaseA 
peptide Substrate Sequence
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Figure 1. Metathesis catalysts used in RCM reaction 
 
Such ruthenium catalysts are known to be useful for olefin metathesis reaction due to their 
stability towards air and moisture as well as compatibility with broad range of functional groups 
35 . Unlike the GI catalyst where both neutral ligands are phosphines, the GII have one of the 
ligands replaced with a N-heterocyclic carbene with a saturated backbone. It was shown to have 
improved catalytic activity than GI catalyst 36 , although the initiation rate is lower 37 . HGII 
catalyst that has substitution of the second phosphine ligand for a bidentate alkylidene, has 
higher thermal stability and tolerance against oxygen and moisture compared to its phosphine-
containing analogue GII, albeit with decreased initiation rate 38 .   
 
First we tested ring closing metathesis reaction for the S5- S5 pair B with the different catalysts. 
The reactions were monitored by LC/MS after cleaving the peptides off the resin. As shown in 
the graph in Figure 2, the GI catalyst showed the best RCM performance, showing almost 90% 
product conversion after 2 hours, while the other catalysts barely achieved 50% product 
conversion after 4 hours.  Therefore, for the conventional stapling system, GI catalyst was 
confirmed as the best choice for the RCM reaction.  
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Figure 2. Comparison of different catalysts for RCM reaction for S5-S5 peptide. Reaction condition: 
30mole % of each catalyst, room temperature, 2 hr for two times 
 
For the S3-S3 pair C, no RCM reaction was observed under any conditions. This result is 
probably because the 4-carbon linker is too short to connect the two positions in an i, i+4 format. 
For the S5-S3 pair E, no reaction occurred at room temperature, and even at higher temperature, 
only with HGII catalyst did the RCM reaction proceed at all (~9% product conversion). 
Interestingly, while E exhibited a very sluggish reaction, the S3-S5 pair D formed stapled product 
readily when certain catalysts were used at elevated temperature. (Figure 3)  
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Figure 3. Comparison of different catalysts used for S3-S5 and S5-S3 metathesis reaction, at 65 oC. 
 
When GI catalyst was used at room temperature, no product was seen after 2 hours of RCM 
reaction, and only about 14 % product conversion was shown after 4 hours of RCM reaction. 
However, when the temperature was elevated to 65oC, ~34 % product conversion was seen after 
2 hours (Figure 4), and the reaction could be pushed to around 80 % after a total of 6 hours of 
RCM reaction.  
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Figure 4.  Temperature dependent RCM reaction. Although no stapled product is seen after 2 hours of 
RCM reaction for S3-S5 pair (i, i+4) at room temperature, with elevated temperature ~34% product 
conversion is observed.  
 
In the same pattern, when GII, GIII or HGII catalysts were used at room temperature, the 
reaction did not proceed for D. However, at high temperature, product conversions of 25%, 34%, 
and >95%, respectively, were shown after 2x2 hours (Figure 5). This clearly shows that the 
HGII catalyst promotes the reaction better than the other catalysts when used at the higher 
temperature of 65 oC. 
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Figure 5. Catalyst dependent RCM reaction. In the RCM reaction for S3-S5 pair(i, i+4) at 65 oC, HGII 
catalyst gives the best yield among the catalysts.  
 
The difference between the two sequences D and E only comes from the swap of the S3 and S5 in 
the i, i+4 positions, which would result in a different olefin position within the hydrocarbon 
bridge in the stapled product; the stereochemistry and  total length of the bridge is the same. 
Therefore, it indicates that the regiochemistry of the linker is important in terms of the RCM 
reaction.  
 
In order to assess the average alpha-helical content of the peptides, circular dichroism analysis 
was performed.  
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Figure 6. Circular dichroism spectra analysis of the 6-carbon i, i+4 stapled peptide. 
 
As shown in Figure 6, the wild type RNaseA sequence A exists as a random coil, but when  
alpha-methyl, alpha-pentenyl amino acids are incorporated into the helix in an i, i+4 phase (B) it 
becomes alpha helical, and more so after metathesis to produce the macrocyclic  bridge (BX) (all 
stapled products are denoted by X). When the alpha-methyl, alpha-propenyl amino acid is 
introduced into the i or i+4 position instead (D & E), helicity is enhanced compared to the wild 
type sequence but the stabilization effect is diminished to a high degree compared to the S5-S5 
pair B. Interestingly, this stabilization effect decreases further when the macrocyclic bridge is 
formed. The S3-S5 stapled peptide pair DX shows a weaker negative maximum around 203-205 
nm. This overall destabillization might come from the fact that the linker length is too short for 
the peptide to retain a normal alpha-helical conformation, and such strain might be reversing the 
helix stabilization effect that came from the introduction of the alpha-methyl, alpha-alkenyl 
amino acids as shown in D & E.   
!20$
!15$
!10$
!5$
0$
5$
10$
15$
20$
25$
185$ 195$ 205$ 215$ 225$ 235$ 245$ 255$
[θ
]×
10
3 $(
de
g$
cm
2 $d
m
ol
!1
)$$
Wavelength$(nm)$
$
B$ A$
BX$ E$
D$ DX$
	  	   16	  
The DX and EX peptides differ only in the position of the olefin within the hydrocarbon bridge, 
closer to N-terminus or C-terminus of the peptide, respectively. To further examine the effect of 
the location of the olefin, we decided to look at the S4-S4 pair, which would have the olefin in the 
middle of the hydrocarbon bridge. In addition we prepared peptides that contained S4-S5 and S5-
S4 and would form a 7-atom hydrocarbon bridge to examine their RCM kinetics as well as the 
helicity of the resulting peptides.  
 
Table 2. 6-carbon & 7-carbon i, i+4 peptides 
 
 
 
As shown in Figure 7, when the GI catalyst was used at room temperature, the S4-S4 pair F 
showed much faster RCM reaction than its S3-S5 counterpart D. For both of these peptides, the 
reaction seems to increase when the temperature was increased to 65 oC. As for the S4- S5 and S5-
S4 pairs, as seen for the S3- S5 vs. S5- S3 pairs, again we observed a prominent difference in the 
RCM kinetics depending on the position of the olefin. The substrate that has the olefin closer to 
the N-terminus, G, shows over 50% product conversion after 2 hours, and completes within 6 
hours. On the other hand, the substrate H that has the olefin closer to the C-terminus only shows 
~42% product conversion even after 6 hours of reaction.  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
D E W A E T A A S3 K F L S5 A H A
F E W A E T A A S4 K F L S4 A H A
G E W A E T A A S4 K F L S5 A H A
H E W A E T A A S5 K F L S4 A H A
RNaseA 
peptide Substrate Sequence
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Figure 7. RCM of i, i+4 peptides with GI catalyst at room temperature. 
 
The rates of metathesis for both G and H increase when high temperature is used, and even H 
reaches over 95% product conversion within 6 hours. (Figure 8) 
 
 
 
Figure 8. RCM of i, i+4 peptides with GI catalyst at 65 oC 
 
The trend of having different properties attributable to the olefin position in the hydrocarbon 
bridge continues in terms of the alpha helical content. In Figure 9, we see spectra ranging from a 
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random coil for unmodified peptide A to a nearly ideal alpha helical profile for the S5-S5 stapled 
peptide BX. Previously we observed that the S3-S5 stapled product DX does not adopt an alpha 
helical structure, but in contrast, FX, which differs from DX only in the position of the olefin, is 
much more alpha helical. By employing a slightly longer linker as in GX and HX, the helicity 
increases even further. Again, compared to S5-S4 stapled product HX, the S4-S5 stapled product 
GX shows stronger alpha helicity, which approaches the helicity of the conventional i, i+4 
stapled peptide BX. (Table 3) The effect of regiochemical variation in the 8-carbon system has 
been studied in the recent paper from Kim group 39 , where it compared S3-S7 and S7-S3 pairs 
with regard to macrocyclic ring closure and alpha-helicity. There again, it showed that while one 
pair, S3-S7, readily undergoes RCM at higher temperature with the product showing substantial 
alpha helicity (49%), the S7-S3 pair does not form stapled product. These results emphasize the 
importance of screening all these attributes with any new stapling system.   
 
 
 
Figure 9. Circular dichroism of 6-carbon and 7-carbon i, i+4 stapled peptides 
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Table 3. Analysis of the circular dichroism results for the 6-carbon and 7-carbon i, i+4 stapled 
peptides.  
 
 
Note that as shown in the previous study by Shafmeister et al. 10 , the 8-carbon i, i+4 stapled 
peptide BX here does not seem to give a very high percent alpha-helicity. However, this might 
be sequence and position dependent, since when the staple position was changed from B 
(position 8 and 12) to R (position 4 and 8), we see the percent helicity for it increased to ~69 % 
as will be shown in the next chapter. Although we have used the same stapling position as in the 
previous study for the sake of direct comparison, it would be worthwhile to repeat the 
experiment in a different position of the same sequence or in a different peptide sequence to see 
if the pattern stays the same.  This would address the feasibility of incorporating the S4- S5 pair 
for stapling peptides instead of S5-S5 if desired.  
 
Chapter 3. 6-carbon i,i+3 stapled peptides 
 
In parallel to the investigation of 6-carbon and 7-carbon i, i+4 stapled peptides in the previous 
chapter, we investigated the feasibility of forming a 6-carbon i, i+3 staple by screening all 
possible combinations of stereochemical configurations at the point of staple attachment to the 
peptide main chain. The hydrocarbon bridge was contracted from 8 to 6 atoms in an asymmetric 
fashion by shortening one tether by two methylenes while leaving the other unchanged. This 
Peptide'Sequence
π→π*''
wavelength'
(nm)
π→π*'
magnitude'
n→π*'
magnitude R'value alpha:helicity
WT (A) 203.0 -13.65 -6.41 0.47 24.6
S3-S5 (DX) 203.5 -8.14 -3.56 0.44 13.6
S4-S4 (FX) 206.0 -8.42 -7.09 0.84 27.2
S4-S5 (GX) 207.0 -11.03 -10.24 0.93 39.2
S5-S4 (HX) 206.0 -10.01 -7.61 0.76 29.2
S5-S5 (BX) 208.5 -12.03 -12.78 1.06 49
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allowed us to analyze simultaneously the effect of translocating the double bond within the 
hydrocarbon bridge of the stapled product. Thus, we employed the four unnatural amino acids, 
alpha-methyl, alpha-pentenylglycine (R5 or S5) and alpha-methyl, alpha-allylglycine (R3 or S3), 
to construct a panel of peptide substrates, based on the RNase A model sequence, that sampled 
all possible permutations that would furnish a 6-carbon macrocyclic bridge anchored at positions 
4 and 7. To facilitate comparison with known stapling systems, we also prepared the 
corresponding unmodified peptides and the modified but unmetathesized peptides as well as the 
Si,i+4S(8)- stapled and Ri,i+3S(8)-stapled versions. (Table 4) 
 
Table 4. Shorter linker i, i+3 peptides 
 
 
The majority of the permuted peptides (K-P) failed to provide any appreciable amount of stapled 
product in our initial screen; these were not pursued further. However, two of the substrates, 
namely I and J, did undergo metathesis to an appreciable extent, yielding products IX and JX. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
A E W A E T A A A K F L A A H A
I E W A R3 T A S5 A K F L A A H A
J E W A R5 T A S3 A K F L A A H A
K E W A R3 T A R5 A K F L A A H A
L E W A R5 T A R3 A K F L A A H A
M E W A S3 T A R5 A K F L A A H A
N E W A S5 T A R3 A K F L A A H A
O E W A S3 T A S5 A K F L A A H A
P E W A S5 T A S3 A K F L A A H A
Q E W A S5 T A A S5 K F L A A H A
R E W A R5 T A S5 A K F L A A H A
RNaseA 
peptide Substrate Sequence
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Substrates I and J possess the same stereochemical configuration (R at position-4 and S at 
position-7) but they swap olefinic tethers between a 3- and 5- carbon version, such that the 
metathesis products IX and JX differ from each other only in the position of the double bond 
within the macrocyclic hydrocarbon bridge. Despite the seeming subtlety of the structural 
differences in I and J and their respective metathesis products, the RCM reactions with these 
substrates showed marked differences (Figure 10). Specifically, RCM on substrate I, having R3 
at position i and S5 at i+3, provided an eightfold higher yield of product than with substrate J, 
which has R5 at position i and S3 at i+3. After the RCM reaction was allowed to proceed for an 
additional 2 hours using fresh catalyst, the difference became even more obvious. In an attempt 
to promote greater product formation in RCM, especially with substrate J, we next explored the 
use of the G-II catalyst and HGII catalyst. We additionally examined the effect of raising the 
reaction temperature from 25 oC to 65 oC with all three catalysts. At 25 oC, both GII and HGII 
proved to be less efficient than GI for RCM of both substrates I and J. When the RCM reactions 
were performed at 65 oC, however, significantly higher conversion was observed using all three 
types of catalyst. Interestingly, HGII, which was nearly inactive at 25oC, exhibited higher 
percent conversions at 65 oC (92% and 71% for I and J, respectively, after 2 hours of RCM 
reaction) than G-I (87% and 43% for I and J, respectively, after 2 hours of RCM reaction). These 
results are reminiscent of those reported by Arora and co-workers in their hydrogen bond 
surrogate alpha-helix-stabilization system 40 .  
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Figure 10. Impact of metathesis conditions on reaction yield and product distribution for 6-carbon 
i,i+3 peptides. Adapted from shim et al. 41  
 
Ring closing metathesis of substrate I actually yielded two cross-linked products (IX1 and IX2) 
in relative ratios that depended on the particular metathesis catalyst employed. GI showed a 
strong preference to form the later-eluting product (ratio of IX1 to IX2 =1/5.8) whereas GII and 
HGII gave a less pronounced inverse selectivity (ratio of IX1 to IX2=1/0.8-0.9). Transfer 
hydrogenation of stapled peptides IX1 and IX2 yields a single-reduced product, IX3, as judged 
by LC/MS analysis, consistent with the notion that IX1 and IX2 are double-bond isomers. In 
contrast to the situation described above for substrate I, the ratio of olefin isomers in the stapled 
products formed with substrate J was not strongly influenced by the catalyst (ratio of JX1 to 
JX2=1/0.6-0.9) Again, transfer hydrogenation of JX1 and JX2 provided a single product, JX3. 
Reduced products IX3 and JX3 had indistinguishable retention times on HPLC, consistent with 
the expectation of these being the same molecule. This is furthermore consistent with the notion 
that IX1, IX2, JX1 and JX2 differ only in the location and/or configuration of the double bond 
within the hydrocarbon bridge; this difference is extinguished upon reduction of the double bond. 
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Incorporation of an Ri,i+3S(8) staple into a peptide has been shown to enhance alpha-helical 
content as efficiently as the Si,i+4S(8) counterpart 30 . To determine the conformational 
preferences of the peptides constrained by the Ri,i+3S(6) staple, far ultraviolet circular dichroism 
(CD) spectra and the percent alpha-helicity of the peptides were measured (Figure 11, Table 5).  
 
 
Figure 11. Circular dichroism spectra. A: CD spectra of the Ri,i+3S(6) stapled peptide having the 
greatest extent of alpha-helix induction and comparison with its unmodified counterpart and the 
previously reported versions having an 8-methylene bridge, Si,i+4S(8) Ri,i+3S(8). B: CD spectra of 
Ri,i+3S(6)-stapled peptides in comparison with their unmodified and reduced counterparts. C: CD spectra 
of Ri,i+3S(6) stapled peptides IX1 and IX2 in comparison with their unmetathesized counterpart I. D: CD 
spectra of Ri,i+3S(6) stapled peptides JX1 and JX2 in comparison with their unmetathesized counterpart J.    
(adapted from Shim et al. 41 ) 
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Table 5. Percent alpha-helicity of the peptides at 20 oC . 
 
 
IX1, the major stapled product of I, exhibited a respectable increase in alpha-helical content 
(55%) as compared to the corresponding unmodified peptide A (25%) The stapled peptide 
bearing an isomeric olefin, IX2, showed only a modest staple-dependent improvement of helicity 
(41%). Unexpectedly, although respective members of the IX and JX series differ only in the 
position of the olefin within the 6-carbon macrocyclic chain, the two displayed dramatically 
different alpha-helix-induction properties, with the IX series being far superior. As the presence 
of the alpha-methyl groups is intrinsically helix stabilizing 18 , the effects of olefin geometry and 
regiochemistry in the IX and JX peptides on helix stability can be ascribed to the macrocyclic 
bridge, certain structures of which are less compatible with the alpha-helix framework than 
others. To test the effect of macrocyclic ring closure, we measured the CD spectra of peptides 
bearing the alpha, alpha-disubstituted amino acids but having no macrocyclic bridge; the 
synthesis of these peptides simply omitted the olefin metathesis step. In the I series, macrocyclic 
ring closure slightly destabilized the helix in the case of IX2 double-bond isomer, and slightly 
stabilized helical structure in the other isomer, IX1. In the case of the J series, closure of the 
macrocyclic hydrocarbon ring actually destabilized helical structure in both isomeric products. 
Furthermore, hydrogenation of the olefin to the product bearing a fully saturated staple, IX3 
(same as JX3), resulted in a significant decrease in helical character (16% alpha-helicity). It 
appears that the particular olefin placement within the macrocyclic ring in the JX series, and also 
Peptide % alpha-helicity
I 50
IX1 55
IX2 41
J 32
JX1 15
JX2 14
IX/JX3 16
A 25
QX 69
RX 74
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the saturated 6-atom macrocycle in IX/JX3, has an especially powerful helix-destabilizing 
effect. These results indicate that the presence, stereochemistry and regiochemistry of the olefin 
moiety in the Ri,i+3S(6) staple are all critical for effective alpha-helix stabilization. Olefin 
geometry is also important with the Si,i+4S(8) staple, but this system is almost completely 
unaffected by saturation of the bridge.  
 
Once again, the RCM yields in the Ri,i+3S(6) system mirror the extent of aqueous helix stability 
in the products, suggesting that the RCM reactions are templated by helix formation. Substrate I 
undergoes much more efficient RCM than J under our standard conditions, and indeed, I yields 
products having greater helix stability than J in aqueous solution. In addition, the most helical 
Ri,i+3S(6) -stapled peptide IX1 is less helical than the corresponding i,i+3 and i,i+4 cross-linked 
peptides having an 8-carbon bridge, and indeed, this 6-carbon system is formed less efficiently 
via RCM than 8-carbon variants. Although the thermodynamic driving force for helix formation 
in DCE is substantially different from that in aqueous solution, both are dependent upon the 
formation of main-chain hydrogen-bonding interactions that could be weakened by introduction 
of a torsionally strained macrocyclic ring. Such torsional strain would both decrease the rate of 
RCM in DCE and diminish helix stability in water. The 6-carbon system has fewer rotatable 
bonds and thereby a lower capacity to avoid repulsive torsional interactions than the 8-atom 
system, explaining the greater sensitivity in the former to structural features of the macrocyclic 
bridge.  
 
Chapter 4. 4-carbon i, i+3 stapled peptides 
We investigated the effect of having 4-atom hydrocarbon bridge in i, i+3 stapled peptides. Here 
again, we utilized the RNaseA sequence so as to be able to compare with the previous stapled 
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peptides. At the same i, i+3 position as in I-P and R, we placed an R3 and S3 pair in substrate S, 
and an S3 and R3 pair in substrate T. 
 
Table 6. 4-carbon i, i+3 peptide sequences 
 
 
For S, no RCM reaction occurred when treated with GI catalyst at room temperature; however, 
elevation of the temperature to 65 oC resulted in over 90% conversion after three 2-hour 
treatments. T did not undergo metathesis even at high temperature. Recall that when S3-S3 was 
introduced in an i,i+4 format (substrate C), no metathesis reaction happened even at high 
temperature. This might be due to the fact that the distance between position i and i+3 that 
bridges a 0.83 turn of the helix is shorter than that of i and i+4 that bridges a 1.11 turn, making it 
possible to accommodate a 4-carbon bridge. (Figure 12) 
 
 
Figure 12. 4-carbon bridge in i,i+4 and i,i+3 formats. 
 
Interestingly, the CD spectra of SX showed a strong negative maximum around 205 nm and a 
weaker (60-75% intense) negative maximum at 222-232 nm. (Figure 13) According to the 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
A E W A E T A A A K F L A A H A
S E W A R3 T A S3 A K F L A A H A
T E W A S3 T A R3 A K F L A A H A
U W A R3 T A S3 A K
RNaseA 
peptide Substrate Sequence
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literature, such a spectrum represents a right handed 310-helix conformation 9,42,43 . Compared to 
an alpha-helix (phi(Φ)=-63, psi(Ψ)=-42) that has i,i+4 hydrogen bonds, a 310-helix (Φ=-57, Ψ=-
30) has i, i+3 hydrogen bonds, having 10 atoms in the pseudo-ring formed by an intramolecular 
i, i+3 hydrogen bond. It is more tightly wound than an alpha helix, thus exhibiting a slightly 
narrower and longer shape 44 . This 310 helix-like conformation is lost when the olefin is reduced. 
When the sequence was shortened to 8 amino acids from the previous 15 amino acid as in U, the 
stapled product UX shows a more intense 310-helix-like conformation, probably due to the fact 
that the 310-helix conformation does not propagate well throughout the length of the longer 
peptide.   
 
 
 
Figure 13. Circular dichroism analysis of 4-carbon i, i+3 stapled peptides. 310-helix conformation is 
shown.  
In related work, Dr. Young-Woo Kim from the Verdine group has shown that when 4-carbon i, 
i+3 staple is put in a peptide sequence consisting of achiral alpha-aminoisobutyric acid (Aib) and 
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glycine(sequence: UGR3GGS3GU and UGS3GGR3GU), it is not only possible to stabilize a 310-
helix conformation, but also to revert the handedness of the helix by inverting the 
stereochemistry from the R3-S3 to S3-R3 combination.  
 
The left-handed helix is a rare motif, constituting only a small percentage of the secondary 
structure pool. However, in a number of cases they have been shown to have a functional or 
structural importance in the protein 45 . Although in the case of the RNaseA sequence T with the 
S3-R3 pair the RCM reaction did not work at all, it might be because there is an innate tendency 
to form a right handed helix. Whereas peptides consisting of L-amino acids preferentially form 
right-handed helices due to the steric hindrance between side-chain atoms and the main-chain 
carbonyl group, with certain amino acids there seems to be more tolerance and a lower energy 
barrier to form a left-handed helix. Thus, we decided to apply this system to an example of a left-
handed 310-helix sequence from nature, to look at the possibility of stabilizing the conformation 
with a 4-carbon S3-R3 staple. 
 
 
 
 
Figure 14. Left handed 310-helix shown in the EGF-A domain of the LDL receptor. (PDB: 3BPS) 
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Table 7. 4-carbon i,i+3 stapled peptide sequences for left-handed 310-helix stabilization 
 
 
We synthesized a model sequence that is derived from the EGF-A domain of LDL receptor that 
is shown to adopt a left-handed 310-helix in the context of the folded protein (Figure 14, Table 
7). Along with the wild type sequence V, all four possible stereochemical combinations were 
tested, including the R3-S3 (W) and the S3-R3 (Y) pairs. (Table 7) Although the RCM reaction 
proceeded for all four sequences, only YX stabilized the left-handed 310-helix. There were two 
stapled product isomers for YX, and only one of them showed the ability to stabilize the 310 
helical conformation. In addition, the ability of the macrocyclic ring to stabilize the 310-helix 
collapsed when the olefin was hydrogenated. (Figure 15) 
1 2 3 4 5 6 7 8 9
V W L D N N G G S S
W W L D R3 N G S3 S S
Y W L D S3 N G R3 S S
LDLR 
peptide Substrate Sequence
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Figure 15.  Stabilization of left handed 310-helix. 
  
These results proved our hypothesis that a 4-carbon macrocylic bridge with the S-R 
stereochemical combination could be used to stabilize a left-handed 310-helix for a naturally 
occurring left-handed sequence. We also made an observation that when we incorporate D-
amino acids instead of L-amino acids and reverse the stereochemistry of the unnatural amino 
acids as well, the CD measurement shows mirror images of those of corresponding peptides. 
(Figure 16) Here, we were able to stabilize a right-handed 310-helix conformation out of peptide 
sequence composed of D-amino acids.  
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Figure 16. Stabilization of right handed 310-helix from a peptide composed of D-amino acids.  
 
Attempt to form a mini-protein of EGF-A domain of LDLreceptor.  
Following the success in stabilizing a left-handed 310-helix as shown above, we continued on to 
synthesize a part of the EGF-A domain of LDL receptor in order to produce a structurally-
stabilized mini-protein that binds to PCSK9. The LDL-receptor is a plasma membrane 
glycoprotein that removes cholesterol-rich LDL particles from the plasma. Its level is known to 
be regulated by PCSK9, which is a 72-kDa protease that is expressed highly in liver. Gain of 
function mutations in PCSK9 result in reduced LDL receptor levels in liver and increased 
susceptibility to coronary heart disease, while loss of function mutations confer protection from 
coronary heart disease. When the PCSK9 protein binds to LDL receptor, it inhibits the recycling 
of the receptor, leading to its degradation. Therefore, PCSK9 is expected to be a good target for 
treating hypercholesterolemia.  
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Therefore, we decided synthesize of mini-protein that mimics the EGF-A domain of the LDL 
receptor to bind PCSK9 and to eventually prevent the degradation of the LDL receptor. In the 
design of the mini-protein, a portion of the EGF-A domain of the LDL receptor that interacts 
with PCSK9 was used. (Table 8) First, the peptides were synthesized starting from the C-
terminus up to 8th residue where the stapling position i is, and then the RCM reaction was 
performed using HGII catalyst for 5 hours at 65 oC (2+2+1 hours, changing into fresh catalyst 
each time). Afterward, the remaining amino acids were coupled to complete the full sequence. 
This strategy was used because the rate of product conversion was faster when the stapling 
position was at the N-terminus of the 19 amino acid sequence than in the middle of the full 26 
amino acid sequence. This might be due to the fact that the peptide consists of L-amino acids, 
which have the tendency to form a right-handed helix. In addition, the ring closing metathesis 
reaction is performed in dichloroethane, an organic solvent that aids right-handed helix 
formation. Thus, the ring closing metathesis reaction to form a left-handed helix would have to 
compete with these opposing factors that favor right-handed helix formation.  
 
Table 8. Part of the EGF-A domain from LDL receptor sequence for left handed 310-helix 
stabilization. 
 
 
Again, there were two RCM products, which probably correspond to the double bond isomers. 
The final peptide products were rather insoluble; in most solvents the peptides precipitated, and 
only when ammonium hydroxide was used was it possible to dissolve the peptide. Since the 
mini-protein consists of 2 disulfide bonds with a 1-3, 2-4 configuration, we had to find an 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
WT G T N E C L D N N G G C S H V C N D L K I G Y E C L
Stapled G T N E C L D S3 N G R3 C S H V C N D L K I G Y E C L
LDLR  
sequence Substrate Sequence
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optimal refolding buffer. After screening a number of conditions, the final refolding buffer 
conditions were set to 50 mM Tris buffer pH 8.5, 10 mM CaCl2, 1mM reduced glutathione 
(GSH), and 50 uM oxidized glutathione (GSSG). These conditions yielded 2-3 distinct refolded 
peptide products. However, after the multi-step procedure to produce the final refolded product, 
the overall yield was very low. Unfortunately, when tested in a cell-based assay to see if the 
peptides are inhibiting the PCSK9 activity at Pfizer, these peptide products did not seem to show 
binding to PCSK9. It is possible that this may be, at least in part, due to the peptides being very 
insoluble and behaving poorly during the assay.  
 
One method we tried to increase the overall yield of the final product was to make a building 
block of the stapled peptide fragment. We reasoned that once the olefin geometry that gives the 
left-handed 310-helix stabilization was determined, it would be possible to improve the overall 
yield of the synthetic mini-protein by separating the two double bond isomers of the building 
block and incorporating the desired fragment into the peptide sequence.  
 
A building block of S3NGR3CS was synthesized with an Fmoc group on the N-terminus and a 
COOH group at the C-terminus. After ring closing metathesis, two stapled products appeared 
that were inseparable with the conventional HPLC solvent system of acetonitrile and water. 
However, when the solvent system was switched to 20-50% methanol in acetonitrile and water, 
the isomer peaks could be separated. (Figure 17) 
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Figure 17. Different solvent system used for separation of two building block isomers. First row, 
solvent A: water(0.1% TFA) solvent B: 20% MeOH in acetonitrile(0.1% TFA). Second row, solvent A: 
water(0.1% TFA) solvent B: acetonitrile (0.1% TFA) 
 
The NMR analysis of the two double bond isomer building blocks was performed with the help 
of Dr. Kazu Hayashi. Each isomer peak was dissolved in DMSO-d6. Although the first peak 
shows broadening of the olefinic signals, the second peak shows J1 of ~15Hz for both olefinic 
protons, which indicates that it is a trans isomer (Figure 18). Thus, we could infer that the first 
peak was the cis isomer, and the second one trans.  
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Figure 18. NMR analysis for determining double bond geometry of 4-carbon i, i+3 stapled peptide. 
A: Proton NMR of 1st peak  B: Proton NMR of 2nd peak C: The olefinic peaks from the 2nd peak shows to 
be trans(E) isomer D: Peptide building block studied in NMR 
 
Although it was the second peak YX2 that had shown a left-handed 310-helix stabilization, the 
peptides used for NMR analysis were protected peptide fragments that were purified using a non-
standard solvent system. We therefore coupled the building block (unstapled and two stapled 
peptides) back onto the resin, and elongated to make the same sequence as in V, W and Y.  
Interestingly, the retention time reversed, i.e the building block that had eluted second produced 
a full peptide that eluted earlier than the other isomer in the acetonitrile/water solvent system. 
When these peptides were analyzed by CD, the peptide containing the 1st building block with cis 
(Z) isomer, now eluting later, showed the left-handed 310-helix stabilization (Figure 19). 
Therefore, we could conclude that the 4-carbon i, i+3 staple that stabilizes the 310-helix probably 
has a Z olefin, which makes sense since there might be too much ring strain for in the case of the 
E isomer.  
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Figure 19. Circular dichroism of the 4-carbon i, i+3 stapled peptide isomers show that the cis-
isomer is stabilizing the 310-helix. 
 
Chapter 5. Conclusions and Future directions 
In these studies, we investigated a 6-carbon and 7-carbon i, i+4 cross-linking system as well as a 
4-carbon and 6-carbon i, i+3 cross-linking system. Although previously it has been shown that 
the RCM reaction for 6-carbon i, i+4 is not possible, we learned that it is possible to make the 
reaction to happen by optimizing the reaction conditions such as the temperature and the 
catalysts. Although we find the 6 and 7-carbon i, i+4 cross-linking systems and the 6-carbon i, 
i+3 cross-linking system to be less effective at stabilizing alpha-helices than the 8-carbon 
stapling system, the most favorable 7-carbon i, i+4 staple and the 6-carbon i, i+3 staple can 
nevertheless induce a considerable degree of alpha-helical character. It has been shown 
previously that inducing the maximum alpha-helicity that a peptide sequence can acquire does 
not always directly relate to the best biochemical or biological assay outcomes 46 , suggesting 
that the alternative stapling systems warrant further investigation in ligand discovery projects.  
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The impetus for this study was provided by the recent reports in both the i, i+4 and i, i+7 systems 
that the atoms of the staple itself can engage residues on the surface of the target, and by the 
observation that staple phasings of i, i+4 and i, i+7 are not always suitable candidates for 
substitution. Therefore, the alternative stapling systems were evaluated with respect to RCM 
kinetics and the conformational stability of the constrained products. Previously it has been 
shown that there is a good general correlation between the yield of peptide in RCM reaction and 
the extent of helix induction in the stapled product 10,30 . This is not unexpected, as the RCM 
reactions are carried out in DCE, a non-polar solvent, and such low-dielectric solvents are known 
to strongly promote alpha-helix formation 47 . This templating effect is presumably a key-driving 
force in the RCM reaction, effectively preorganizing the RCM substrate in a conformation that 
increases the local concentration of the reacting olefins relative to that in an unstructured or 
alternatively structured peptide. This templating effect, together with kinetic reversibility of 
RCM, also guarantees that torsionally strained cross-link configurations will not be formed in 
high yields. Thus, the yield of product in the RCM reaction provides a rough preliminary 
indicator of helix stability in the product. Another motivation for this study came from the 
hypothesis that the shorter carbon linkers would alleviate the aggregation problem, and this could 
be examined by comparing the light scattering signals of the stapled peptides with different 
linker lengths.  
 
We also found that the presence of an olefin, and its position and geometry, are all critical factors 
in achieving maximal alpha-helix stabilization of a peptide using the 6-carbon and 7-carbon i, 
i+4 cross-link and 6-carbon i, i+3 cross-link. Interestingly, it was apparent in a number of cases 
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that not only the length and stereochemistry, but also the position, of the olefin within the bridge 
affected the RCM kinetics as well as the helical induction. When the olefin of the staple was 
closer to the N-terminus than to the C-terminus, the ring formed more readily and the resulting 
macrocycle was more alpha-helical. In addition, when the olefin would end up in the middle, the 
substrate showed even better performance in the RCM reaction as well as higher alpha-helicity. 
One possible reason to explain this phenomenon might be that steric hindrance of the catalyst 
with the peptide makes it harder to form a bridge when the linker is shorter (i.e. allylglycine).  
This would explain why the staple forms better when the linker is symmetric. The reason why 
the 3-5 or 4-5 pair shows better RCM reaction than 5-3 or 5-4 pair, might come from the 
possibility of a Ru-Carbene complex from the allylic sidechain or butenyl sidechain forming a 
stable chelate with the carbonyl oxygen within the same residue, as suggested in a similar study 
where S3-S7 and S7-S3 in i, i+4 phasing was investigated 39   Such an interaction would form an 
intermediate pseudo 6 and 7-membered ring, respectively, which would make it harder for the 
RCM reaction to occur when the complex is facing the opposite direction as in the case where 
allylglycine or butenyl glycine is at the latter position.  
 
In addition, we have shown that by using the 4-carbon i, i+3 stapling system, it is possible to 
stabilize a right-handed 310-helix, and to similarly stabilize a left-handed 310 helix when the 
stereochemistry of the cross-linking amino acids are reversed. Previously, stabilization of a 310-
helix has been observed using ring-closing metathesis reaction 9  or click chemistry 48 , however 
in both studies the sequences contained the non-proteinogenic amino acid Aib which induces a 
310-helical conformation when present in a large fraction in a peptide 18 . 
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Although additional experiments examining proteolytic degradation or cell permeability should 
be performed to complete the story, we hope these initial studies on different stapling systems 
would aid in finding the sweet spot for the most optimized binding between the stapled peptides 
and the target protein. In addition to the conventional way of screening staple positions, we could 
also try removing one or two carbon atoms from the linker in case the bridge itself forms a 
contact with the target. In addition, the cis isomer of the 4-carbon i, i+3 stapling system can be 
used if the critical binding interaction relies on a 310-helical format. By reversing the 
stereochemistry of the unnatural amino acids from the R, S combination to the S,R combination, 
we have proved the possibility of stabilizing a left-handed 310-helix for naturally occurring left-
handed helices. This also suggests that it might be possible to stabilize a left-handed alpha-helix 
in an i, i+4 format as well for certain sequences.  
 
Chapter 6. Experimental Method 
 
Peptide synthesis 
All peptides were synthesized using Fmoc chemistry on Rink Amide MBHA resin with a loading 
capacity of 0.50 mmol/g 19 . The resin was swelled with NMP for 15 min before use. The Fmoc 
protecting group was removed by treatment with 25% piperidine in NMP (2 x 10min) Natural 
amino acids were coupled for 45 min using HCTU as the activating agent (4.75 equiv.), five 
equivalents of Fmoc-protected amino acid, and 10 equivalent of DIPEA in NMP. For the 
coupling of olefin-bearing unnatural amino acids, a reaction time of 2 h was used with Fmoc-
protected amino acid (3.0 equiv), HCTU (2.85 equiv.), and DIPEA (6.0 equiv.). These unnatural 
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amino acids were bought from Okeanos Tech. After each coupling or deprotection reaction, the 
resin was washed with DCM (1x1min), NMP (1x1min), DCM (1x1min), and NMP (1x1min). 
 
 
Metathesis reaction 
Ring-closing metathesis of the fully elongated, fully protected, resin-bound peptides was 
performed using 20 mol % of either Grubbs first- or second-generation catalyst or Hoveyda-
Grubbs second-genetration catalyst in degassed DCE for 2h at 25 oC or 65 oC. For the reactions at 
65 oC, the reaction vessels were shaken in a temperature-controlled environment. The reactions 
were monitored by liquid chromatography/mass spectrometry (LC/MS) after cleavage of the 
peptides from a resin aliquot. For the second round of metathesis, the resin was treated with fresh 
catalyst for an additional 2 h. After each round of metathesis, the reaction solution was drained 
and the resin was washed first with DCM (5x2min) and then with NMP (3x2min). After the 
Fmoc group was removed using 25% piperidine in NMP, the N-terminal amino group was 
treated with 30 equivalents of acetic anhydride (102 g/mol, 1.08g/ml) and 60 equivalents of 
DIPEA (129.25 g/mol, 0.742 g/ml) in NMP for 45 min at room temperature. The synthesis resin 
was washed with DCM (1x1min), NMP (1x1min), DCM (3x1min), and methanol (3x2min) and 
dried in vacuo overnight.  
 
Olefin hydrogenation 
The hydrogenation of the olefin in the hydrocarbon bridge was performed by adding 200 ul of 
0.7 M TIBSH(2,4,6 tri-isopropyl benzenesulphonyl hydrazide) and 1.4 M piperidine in NMP to 
the peptides on resin. The reaction tube was sealed tightly and put in 55 oC incubator. The 
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progress of the reaction was monitored by doing test cleavage and injecting the product into 
LC/MS after 2 hours. The same procedure was repeated until the olefin was completely reduced. 
 
 
Peptide purification 
The peptides were deprotected and cleaved from the resin by treatment with a mixture of 
TFA/TIS/water (95/2.5/2.5) for 2 h. In the case where cysteine was present in the peptide, a 
cocktail of TFA/TIS/EDT/water was used instead. After the majority of volatile material was 
removed under a gentle stream of nitrogen in a fume hood, the peptide products were 
precipitated by addition of a 1:1 mixture of n-pentane and diethyl ether. The precipitate was 
suspended by vigorous vortexing and collected by centrifugation. The pellet was allowed to air-
dry until the traces of liquid ether were no longer visible, the products were dissolved in a 1:1 
mixture of acetonitrile and water, and the resin was removed by filtration. The products were 
purified by reverse-phse HPLC using a Zorbax C18 column (Agilent, 5 um, 9.4x250 mm) and 
characterized by LC/MS using a Zorbax C18 column (Agilent, 3.5 um, 2.1 x 150 mm) and amino 
acid analysis.  
 
Circular Dichroism 
Peptides were dissolved in 20 mM potassium phosphate buffer (pH 6.5), and the concentrations 
as determined by absorbance spectroscopys (the extinction coefficient, λ280, for tryptophan 
=5960/M/cm) 49 were adjusted to 70-110 uM. Circular dichroism spectra were collected on a 
Jasco J-710 spectropolarimeter (Japan Spectroscopic Corporation, Tokyo, Japan) equipped with 
a temperature controller using the following standard measurement parameters: 0.5 nm step 
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resolution, 20 nm/seconds speed, 10 accumulations, 1 second response, 1 nm bandwidth, 0.1 cm 
path length. All spectra were converted to a uniform scale of molar ellipticity after background 
subtraction. Curves shown are smoothed with standard parameters. 
 
Building Block synthesis 
Acid-labile 2-chlorotrityl chloride resin with a loading capacity of 1.2 mmol/ g was used for 
building block synthesis.  For the first amino acid residue attachment, 3 equivalents of fmoc-
amino acid mixed with 7.5 equivalent of DIPEA in dry DCM was used. The coupling reaction 
went for 30-60 min at room temperature, and afterward the resin was washed with 
DCM/MeOH/DIPEA (80:15:5) three times, 15 min each. The subsequent couplings are the same 
as in conventional Fmoc SPPS. For cleavage reaction, mixture of HFIP:DCM (1:4) was used to 
obtain the protected peptide fragments. The purified building block was put back onto the resin 
in the same way, but this time using about 1 equivalent of the building block mixed with 2.5 
equivalent of DIPEA in dry DCM, and capping the remaining linkers on the resin with MeOH.  
 
NMR 
1H NMR spectra were measured in DMSO-d6. Mass spectral data were obtained at the Harvard 
Mass Spectrometry Facility.   
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Part II. Development and structural studies of direct peptide 
inhibitors of Ras 
 
Chapter 1. Ras protein 
1-1. What is Ras? 
 
Ras is a molecular switch that cycles between on and off depending on the guanine nucleotide 
binding mode. When the bound GDP dissociates and exchanges for GTP which has a higher 
concentration in the cell, Ras switches on. This reaction is mediated by guanine nucleotide 
exchange factors (GEF) and modulates various intracellular signaling pathways regulating cell 
growth, differentiation and proliferation via effector proteins 50,51 . Conversely, the intrinsic 
GTPase reaction hydrolyzes GTP to GDP, which is accelerated by about five orders of 
magnitude by association with a GTPase activating protein (GAP) 52  53,54 , which causes Ras to 
switch off.  
 
The guanine nucleotide binds and hydrolyzes in the 20-kD G domain of Ras. It consists of 5 
alpha-helices and 6 beta-strands, and the guanine nucleotide binding site shows conserved 
sequence elements, such as the N/TKXD motif that interacts with the nucleotide base or the 
phosphate-binding loop (P-loop) that binds to the phosphates of the guanine nucleotide 55 . The 
high affinity binding of guanine nucleotide to Ras is due to the interaction of the phosphates with 
the P loop and Mg2+ ion. To promote nucleotide exchange GEFs interact with the switch I and 
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switch II regions by inserting residues close to the P loop and Mg2+ binding area and creating a 
structural change that inhibits the binding of phosphates and Mg2+. The disturbance of the P loop 
seems to be the major reason for the drastically decreased nucleotide affinity 56  
 
The differences between the structures of GTP-bound Ras and GDP-bound Ras lie in the two 
switch regions, switch I (residues 32-38) and switch II (residue 59-67). The crystal structures of 
H-Ras show that Ras contacts the γ-phosphate via the main chain NH groups of Thr35 in switch 
I and Gly60 in switch II 57 (Figure 20). 
 
Figure 20. GTP-bound Ras. The Ras domain is shown in cartoon representation, and the nucleotide and 
magnesium ion are shown in ball-and-stick representation. Threonine 35 in switch I (yellow) and glycine 
60 in switch II (green) are shown in sticks. The main chain NH groups of Thr35 and Gly60 are interacting 
with the γ -phosphate of the GTP analogue. (PDB 5P21) 
 
When GTP hydrolyzes, the gamma phosphate is released and induces increased flexibility in the 
switch regions 55 , thus resulting in allosteric conformational changes 58  (Figure 21).  
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Figure 21. GDP-bound Ras. The Ras domain is shown in cartoon representation, and the 
nucleotide in ball-and-stick representation. Threonine 35 in switch I (yellow) and glycine 60 in 
switch II (green) are shown in sticks. Unlike in the GTP-bound form, no interaction is shown 
between Thr35 and Gly60 with guanine nucleotide. (PDB 4Q21) 
 
This can be described as a ‘loaded spring mechanism’, where the release of the γ-phosphate from 
the hydrolysis of GTP results in the two switch regions relaxing into a GDP-specific 
conformation 55  (Figure 22). 
 
Figure 22. Loaded-spring mechanism of Ras. A. Schematic diagram of Ras in GTP form.  B. 
Schematic diagram of Ras in GDP form. With the release of γ-phosphate from GTP, the interactions with 
switch I and switch II that were present in GTP-bound Ras are absent, conferring flexibility in the switch 
regions.  
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Effectors for Ras interact more tightly when Ras is in the GTP-bound form rather than the GDP-
bound form; such nucleotide-dependent recruitment of effectors in a major signal transduction 
mechanism. As described above, in the GDP-bound state, flexibility of the switch I region 
increases significantly, which is shown to be related to the decreased affinity to effectors 59 . One 
well-known effector that presents a characteristic Ras-binding domain (RBD) is the Raf protein 
kinase, which binds to Ras with 3.5nM affinity 60  by forming an interprotein beta sheet between 
the two molecules  61 . Ral-GDS is another example 62  that has ubiquitin-like domain that binds 
to Ras in a way similar to that of Raf. While these effectors are shown to bind mostly to switch I 
region of Ras, another well-known Ras effector PI3K is shown to make critical interactions with 
switch II region of Ras as well, which produces structural changes that might affect its 
phospholipid substrate binding and catalytic activity. (Figure 23) 
 
Figure 23. Ras families binding to their effectors. Ras is on the right, colored in yellow, and its 
effectors on the left, in orange-related colors. The residues within 4A of Ras are colored in cyan, and the 
residues within 4A of the effectors are colored in red. A: Rap1A-RasRBD complex (PDB:1C1Y) B: Ras-
RalGDS complex (PDB: 1LFD) C: Ras-Byr2RBD complex (PDB:1K8R) D: Ras-PI3K complex(PDB: 
1HE8). The effectors are shown to be interacting with Ras via beta-sheet complementation with its switch 
I region. Interactions with switch II are also shown in C & D.  
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1-2. Ras and tumor formation  
 
The Ras genes are known to be the most frequently mutated oncogenes in human cancer 63  
(Table 9). There are four isoforms of Ras: Kirsten rat sarcoma virus (K-Ras) 4A, K-Ras 4B, 
Harvey rat sarcoma virus (H-Ras) and Neuroblastoma rat sarcoma virus (N-Ras). These Ras 
proteins are highly conserved, especially in their effector binding regions where they are actually 
identical. They mostly differ only in the C-terminal 25 amino acids, the hypervariable region that 
is responsible for anchoring Ras into the cell membrane 64 . K-Ras-4A and K-Ras 4B are actually 
encoded by the same gene, and only differ in their fourth exons. Although the isoforms are 
highly similar, there are actually different frequencies of mutations of K-Ras, N-Ras and H-Ras 
in human cancer (Table 9). Each isoform is correlated specifically with certain types of cancer; 
K-Ras mutation is frequent in pancreatic, colon, small intestinal and lung cancer, H-Ras in 
urinary tract cancer, and N-Ras in skin cancer. However, among these K-Ras is known to be the 
major Ras gene mutated in about 30% of human cancer, with poor prognosis and 
chemoresistance 65 . Although it is not known for sure why K-Ras mutation correlates more 
highly with cancer than the other isoforms, it might be due to the differential regulation of the 
gene expression during development rather than the properties of the proteins themselves 66 .  
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Table 9. Frequency of Ras isoform mutations in selected human cancers. Data adapted from Stephen 
et al 63 . 
 
 
Missense mutations at codons 12, 13 or 61 in Ras are known to promote oncogenesis by 
inhibiting GAP-mediated GTP hydrolysis. The active site of Ras shows a conserved glutamine 
residue Q61 near the γ-phosphate. Since it plays an important role in stabilizing the transition 
state of the hydrolysis reaction by interacting with a water molecule that bridges one of the 
gamma-phosphate oxygen atoms to OH group of Y32 67 , mutation of this catalytic residue is 
known to be oncogenic. Another important residue is G12 in the P-loop, where a codon 
substitution sterically blocks GAP mediated GTP hydrolysis. This inhibition of GTP hydrolysis 
leads to a large proportion of stabilized GTP-bound mutant Ras proteins, resulting in constitutive 
activation of the Ras signaling pathway. 
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1-3. Strategies for Ras inhibition  
While the significance of targeting K-Ras for cancer therapeutics is evident, to date there have 
been no reported high affinity inhibitors of Ras. One previous attempt to inhibit Ras activation 
was to use a farnesyltransferase inhibitor to impede posttranslational modification Ras and 
prevent insertion into the inner leaflet of the cell membrane 68 .  However, it was found that 
farnesyltransferase is not required for insertion of K-Ras and N-Ras into the membrane; 
geranylgeranyltransferase is alternatively capable of modifying Ras for membrane insertion 69 . 
Another failed strategy for Ras inhibition was the production of a Raf inhibitor that led to 
paradoxical activation of Raf kinase 70 . Another possible targeting strategy for Ras would be to 
block the GTP binding site or disrupt nucleotide exchange. Since there is a high level of GTP in 
cells and Ras binds GTP with picomolar affinity, however, any strategy targeting the GTP 
binding site would be very difficult.  
 
The Shokat group recently developed a covalent catalytic site-inhibitor for Ras that undergoes 
through electrophilic attack to covalently modify the non-natural cysteine present in K-Ras 
G12C. By engaging a binding pocket beneath the switch II region, the inhibitor induces a 
preference for Ras to bind GDP and adopt its inactive state 71 . Importantly, this work has shown 
that the Ras proteins exist in in dynamic and flexible states, revealing the potential for new 
therapeutic strategies that exploit this malleability. The Walensky group produced a stapled 
SOS1 helix that directly inhibited the interaction between K-Ras and SOS1, leading to inhibition 
of nucleotide association and a decrease in K-Ras signaling 72 . 
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Here we describe our ongoing attempts to develop peptides that directly block the recruitment of 
effector proteins to the Ras effector domain 73  as a means to suppress Ras signaling in cancer 
cells.  
 
 
Chapter 2. Directed evolution via yeast surface display  
 
2-1. Yeast surface display  
 
The surface of the Ras effector domain does not have an obvious hydrophobic pocket that could 
be targeted by small molecules, and as shown in figure this domain interacts with effector 
proteins via beta-sheet complementation. Therefore with limitations in using rational design for 
discovering inhibitors of this protein-protein interaction, we performed directed evolution of 
peptides using yeast surface display. 
 
Yeast surface display system has been developed Wittrup lab as a powerful means for expressing 
104~105 copies of a heterologous protein on the cell wall of yeast Saccharomyces cerevisiae 
using the a-agglutinin system.  74  75 It has been used for many interesting applications such as 
affinity maturation through repeated rounds of error-prone PCR and fluorescence activated cell 
sorting (FACS), screening cDNA libraries  76  or engineering proteins for improved production 
and stability 77,78 . Compared to phage display, yeast display has advantages in that it utilizes 
eukaryotic secretory machinery that enables post-translational processes such as oxidative 
folding or N-glycosylation. In addition, the ability to use multiple fluorescent channels in the 
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FACS step of yeast surface display makes multiparameter sorting possible. For example, with a 
two-label system we can check both the binding level and the expression level by flow cytometry, 
enabling normalization of binding to expression level and minimizing artifacts that might come 
from host-expression-bias 79 . Therefore, we expect to obtain proteins with both increased affinity 
and stability by using iterative rounds of random mutagenesis and directed evolution.  
 
 
Figure 24 Yeast surface display. The binding of Aga2P-fused peptide (blue) to Ras protein (orange) is 
detected using secondary reagent such as streptavidin conjugated to fluorophore, which would bind to the 
biotinylated Ras. Expression of the peptides is detected through immunofluorescence labeling of 
hemagglutinin (HA) epitope tag (Beige).  Adapted from Chao et al 80 .  
 
As shown in Figure 24, Aga1P is anchored to the cell wall, and Aga2P is linked to Aga1P via 
disulfide bonds. The C-terminus of Aga2P can then be fused to the N-terminus of a protein of 
interest through a flexible linker such as (GGGGS)n. The diversity in the library constructs is 
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generated by PCR. Using this system, it is possible to express and screen genetically encoded 
combinatorial libraries of peptides against a soluble ligand in a rapid and quantitative way using 
FACS. By limiting the concentration of the soluble target, it is possible to enrich for mutants 
with high affinity. In addition, with the genotype-phenotype linkage it is straightforward to 
identify initial binders and to further optimize the sequence with successive rounds of directed 
evolution.  
 
2-2. Scaffolds 
We initially began the yeast surface display experiment using four different scaffolds: the avian 
pancreatic polypeptide sequence, a short beta hairpin sequence, the PI3K knuckle region and the 
scyllatoxin sequence. These initial libraries for screening were designed by Dr. John McGee in 
Verdine group.  
 
A. Avian pancreatic polypeptide scaffold 
Avian Pancreatic Polypeptide (aPP) is a well established natural folded polypeptide that contains 
a polyproline II motif and an α-helical region. The interaction between these two helices 
stabilizes the fold, and it is possible to modify the exposed face of the α -helix to achieve 
interaction with a target 81,82 . Thus, we used mutagenesis to randomize residues in the α –helix 
residues that face outward and have no structural role, and three arginines were incorporated into 
the polyproline helix to enhance cell permeability (Figure 25). This arginine mutant of aPP was 
also shown to be more thermally stable than the original aPP protein, which might help to 
improve the quality of the library.  
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Figure 25. aPP scaffold for yeast display. A: Stabilized aPP with the hydrophobic residues in the core. 
B: the template used for yeast display. Residues in magenta are those that underwent random mutagensis, 
and residues in green have been mutated to arginine for possible aid in cell permeability (PDB: 1PPT) 
 
B. Beta hairpin scaffold 
A Beta hairpin template was also used with the intention of taking advantage of the tendency of 
Ras to bind partners through beta sheet complementation. The conformation of this scaffold was 
constrained by a disulfide bond and cross-strand pair residues that packed together to produce a 
structural stabilization effect 83,84 . The residues on one face of the beta hairpin were mutated to 
optimize packing, and the residues on the other face were randomized for target interaction 
(Figure 26). 
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Figure 26. Beta hairpin scaffold for yeast display. A: Beta hairpin structure in cartoon representation. 
B: The residue pair in cyan color packs together, which is important for stabilization of the structure, 
along with the disulfide bond. Therefore, those residues were mutated to amino acids that would 
contribute to hydrophobic interaction. The residues in magenta color went through randomized mutation. 
(PDB: 1N0C) 
 
C. PI3K scaffold 
The Ras binding domain of PI3K, a well-known Ras effector, consists of a beta strand followed 
by an alpha helix that exhibits most of the interactions between Ras and PI3K 85 . The PI3K 
knuckle library was formed from random mutagenesis using error-prone PCR. (Figure 27) 
 
Figure 27. PI3K for yeast display scaffold. A: Interaction between Ras(light purple)and PI3K(light 
pink). B: The binding domain of the PI3K and Ras has been enlarged. The Ras binding domain residues 
of PI3K that were used as a scaffold for yeast display are colored in hot pink. (PDB:1HE8) 
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D. Scyllatoxin scaffold 
The scyllatoxin peptide shows a structure similar to that of the abovementioned PI3K scaffold, 
with a N-terminal helix followed by an antiparallel beta-strand. The fold seems to be stabilized 
by three disulfide bonds 86,87 . In the scyllatoxin scaffold, residues from each face of the scaffold 
were mutated for binding to Ras. (Figure 28) 
 
 
Figure 28. Scyllatoxin scaffold for yeast display. A: The scyllatoxin sequence consists of an alpha helix 
followed by a beta-hairpin. B. There are three disulfide bonds in the structure that seem to aid in the 
stabilization of the scaffold. C,D: Two opposite faces of the scaffold were mutated for binding to Ras. 
(PDB:1SCY) 
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2-3. Library generation & initial screens 
 
The DNA library containing the scaffold sequence of interest was linked to the linearized 
pCTCON2 vectors via homologous recombination and transformed into yeast strain EBY100 88 . 
(Figure 29) The proteins were fused to the C-terminus of Aga2P, the expression of which was 
under the control of galactose-inducible promoter. 
 
 
Figure 29. Plasmid library for yeast surface display system. The linearized DNA library fuses with 
linearized pCTCON-2 vector via homologous recombination. 
 
 
The transformed yeast cells were grown in SDCAA media, where they used glucose as a carbon 
source to repress the expression of the heterologous protein in case of toxicity to the cells. For 
induction of the Aga2P protein fusion on the cell surface, galactose-containing media was used.  
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Figure 30. GTP and its analogue. A: Guanosine triphosphate B: 5’-Guanylyl 
imidodiphosphate(GppNHp). Also called GMP-PNP 
 
The yeast libraries were screened for binding to the Ras G12V mutant with GppNHP, a non-
hydrolyzable GTP analogue where one of the oxygen atoms is replaced by an amine. (Figure 30)  
This Ras protein was biotinylated so that it could be detected with PE fluorescence-labeled 
avidin. Streptavidin-allophycocyanin (SA-APC) and neutravidin-phycoerythrin (NA-PE) were 
used in alternation in order to prevent the enrichment of peptides that bind to them. The HA 
epitope tag at the N-terminal of the peptides was labeled with FITC to measure the expression 
level of the peptides on the yeast cells. The size of each initial library was approximately 107-108. 
In order to maximize the probability of isolating rare clones, any yeast display library should be 
oversampled by 10-fold. 75  As typical FACS sorting rates are 103~104 cells/sec, we performed 
the initial screening for Ras binders using magnetic-activated cell sorting (MACS), which is 
capable of sorting 109 cells at a time.   This was intended to ensure that all unique clones in the 
library would be screened. After the initial MACS screen using 3uM Ras, subsequent sorting was 
performed by FACS. Note that background fluorescence that is equivalent to that of the negative 
control (Figure 31) is shown in all FACS data. This negative peak might come from the cells in 
which the secretory apparatus is saturated and blocked with misfolded protein. 89  Fortunately, it 
is known that this unlabeled cell population does not seem to affect the library screening.  75  
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Figure 31. Negative controls in FACS sorting in yeast surface display experiment. Double negative 
control, control for surface expression level and control for binding level are shown from left to right.  
 
In the first few rounds of FACS, sorting gates were set generously (~top 5%), whereas a more 
stringent gate (top 0.1~1%) was used for the following sorts. For the PI3K library, the protein 
expression level was expected to be low due to the instability of the peptide. Thus, for the first 
screening, the yeasts showing expression of the protein were initially collected using the FLAG-
tag at the C-terminal of the protein and then analyzed for binding to Ras. After about total of 
seven rounds of sorting for each library, (Figures 32-35) most libraries began to show some 
enrichment.  
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Figure 32. Screening of aPP library by FACS 
 
Figure 33. Screening of beta hairpin library by FACS 
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Figure 34. Screening of PI3K library by FACS 
 
 
 
 
Figure 35. Screening of scyllatoxin library by FACS 
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To ensure that the enrichment was for Ras binders, a test FACS was performed with the same 
conditions but without the Ras protein. If the enrichment still existed even in the no Ras control, 
it indicated that the peptides might be secondary reagent binders. Another control FACS 
experiment was performed by incubating the cells with K-Ras that had been pre-mixed with a 
large excess of Raf, to see if the enriched peptides were competing with Raf for the binding site 
on Ras. If this were the case, it was expected that there would be a decrease in the level of 
binding signal. (Figure 36) 
 
 
Figure 36. Control experiments. A: Peptide will compete with Raf if the binding site for Ras overlaps. 
B: If the peptide is binding to another region of Ras, the Raf will stay and there won't be decrease in the 
binding signal. C: if the binding signal does not diminish in the absence of Ras, it suggests that the 
peptide has been evolved as a secondary reagent binder.   
 
From the results of the control experiments, we observed that the weak binding signal that was 
shown in the PI3K library (Figure 37) and Scyllatoxin library (Figure 38) stayed the same in the 
Ras-Raf preincubation control and the no Ras control experiment, which suggested the absence 
of real Ras binders. In the beta hairpin library (Figure 39), although the signal diminished in the 
no Ras control experiment, the binding level seemed to stay the same in Ras-Raf preincubation 
control experiment. This indicated that even if the enrichment was for peptides that bind to Ras, 
they might not be able to compete with the effectors.  On the other hand, for the aPP library 
(Figure 40), the signals clearly diminished in both control experiments, which implied 
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enrichment for Ras binding peptides that can compete with Raf for binding to Ras. Therefore, we 
decided to pursue further the hits that came from the aPP library.  
 
 
Figure 37. PI3K library control experiments 
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Figure 38. Scyllatoxin library control experiments 
 
 
 
Figure 39. Beta hairpin library control experiments 
	  	   64	  
 
 
Figure 40. aPP library control experiments 
 
2-4. Screening with aPP libraries 
 
One of the benefits of the yeast display system is that with the genotype-phenotype linkage, it is 
easy to figure out the sequence of the binders. By sequencing the hits we got from the first aPP 
library (221 library), we saw that some residues had already strongly converged to specific 
amino acids. (Figure 42) For instance, position 21, 24, 28, 29 and 32 that were randomly 
mutated in the 221 library, has converged to single amino acid residue histidine, tryptophan, 
tryptophan, asparagine and tyrosine, respectively.  
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Using the hit sequences as another starting point, error-prone PCR was performed to introduce 
mutations into the sequence to generate a new library. The error-prone PCR method is often used 
to introduce high numbers of mutations into DNA sequences to create a combinatorial library 
based on a single gene 90 . The resulting library was named the 223 library.  For the 223 library, 
the Ras concentration used for MACS was decreased to 100-250 nM compared to the 3 uM used 
for the 221 library screening. For subsequent FACS sorts, 10-50 nM Ras was used depending on 
the robustness of the enrichment. Additionally, 5% (v/v) human serum and 100 ug/ml salmon 
sperm single stranded DNA (ssDNA) were used as blocking agents to prevent non-specific 
binders that might come from hydrophobic interactions.  
 
After a total of 7 rounds of sorting, we performed control experiments. In Figure 41 A, where 
the screening and sorting was done in 50 nM Ras, the enrichment of the peptides clearly 
decreased when there was no Ras. However, when the screening and sorting was done in 5nM 
Ras, enrichment was observed even in the absence of Ras as shown in Figure 41 B. This 
observation clearly indicated that the enrichment was resulting from the selection of secondary 
reagent binders.  Therefore, even for the same library, it was important to carefully choose the 
concentration of the target protein in order to ensure selection for target binders. In Figure 41 C, 
a 300nM Ras-5 uM Raf preincubation experiment showed a shift downward of the enrichment, 
implying that the enriched peptides were competing for the effector binding domain. Figure 41 
D shows a similar experiment in which GFP-labeled Raf was used. Since the GFP is detected in 
the same fluorescence channel as FITC, we chose the GFP fluorescence channel and APC 
channel to look at the binding levels to Raf and Ras, respectively. Again, we saw that the binding 
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to Ras diminished upon Raf preincubation, and the lack of a GFP signal confirmed that the 
peptides were not binding to Raf.   
 
 
Figure 41. Control FACS experiments for the 223 library. red plots: FACS experiments with yeast 
cells incubated with designated concentration of Ras. Blue plots: no Ras (A & B) or 300 nM Ras+5 uM 
Raf preincubation (C & D). Note that in D, GFP-Raf was used, thus we looked at the Ras binding signal 
and Raf binding signal in FACS.  
 
The hits from the 223 library were mini prepped and sequenced, and the results are summarized 
in Figure 42. Here we see that the position 16 and 18 has converged to serine and glutamate 
respectively, and new residues such as arginine for position 26 and alanine for the position 33 
appeared. 
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Using each of these sequences as templates, we conducted another error-prone PCR to put 
mutations into the hit sequences and make new libraries for the next round of screening and 
sorting. The 224A library is based on the 223-1 sequence, while the 224B library is based on the 
223-2 sequence.  
 
For the screening of the 224 library, we dropped the Ras concentration down to 25 nM for the 
initial screening, and further went down to 5 nM. After 7 to 10 rounds of sorting, we saw that the 
224A library converged to one sequence, 224A-1, and the 224B library converged mostly to 
224B-1 although there were a few 224B-2 sequences that have PRR insertion in the beginning of 
the sequences. Four more subsequent screening rounds with the 224B library with a lower Ras 
concentration of 5 nM yielded only 224B-1, suggesting that 224B-1 might be a stronger binder 
than 224B-2. In 224A-1, there were Y10C and F23Y mutations that weren’t seen in the previous 
sequences. In 224B-1, we again observed the Y10C mutation, and although 223-2 sequence was 
the template for 224B library, we can see that the residues in position 22 and 26 converged to 
those that were already evolved in the 223-1 sequence, suggesting that those residues contribute 
more to Ras binding.  
 
We set up two strategies for the next libraries. The first one, 225 library, was to combine and 
shuffle all the different amino acids that came out in the 224 library hit sequences without further 
mutation. In case the cysteine mutation in the 10th residue was coming from an artifact such as 
forming disulfide bond with one of the cysteine residues in Ras, we used tyrosine instead of 
cysteine at that position in the library. For the second one, 226 library, we used error-prone PCR 
in 225 library to introduce mutations into the sequence.  
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After three rounds of screening at 100 nM Ras, the 225 library mostly converged to one 
sequence, 225-1. After five rounds of sorting beginning at 100 nM Ras and tapering to 20 nM 
Ras, the 226 library showed mostly peptides with amino acid combinations that were already 
shown in the previous library hits. The dominant residues were the same ones as in 225-1, such 
as glutamate at position 22, tyrosine at position 23 and isoleucine or valine at the position 17. A 
dramatic change was revealed in position 10, where again cysteine emerged dominantly over the 
original residue tyrosine even though it was not in the original amino acid mixtures. The results 
of the evolution will be explained further with the structures of the complex of Ras (G12V) 
GppNHp and the peptides in the following section.  
 
 
 
Figure 42. aPP library hit sequences. X: site of directed mutagenesis. Red color used to show the 
residues that came out from the directed evolution screens, and the ones that have converged to a strong 
consensus have been highlighted. The green color indicates the residues that have been shuffled from a 
set of amino acids that came out from previous rounds. (This particular numbering system was used to be 
consistent with that of the structural data) 
Clone
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Original aPP G P S Q P T Y P G D D A P V E D L I R F Y D N L Q Q Y L N V V A
Library template G P R R P R Y P G D D A P V X D L X X F X A X L X X Y L X V V A
221-1 G P R R P R Y P G D D A P V E D L H A F W A A L W N Y L Y V V A
221-2 G P R R P R Y P G D D A P V G D L H E F W A Q L W N Y L Y V V A
221-3 G P R R P K Y P G D D A P V E D L H W F W A A L W N Y L Y V V A
223-1 G P R R P R Y P G D D A S V E D L H E F W A R L W N Y L Y A V A
223-2 G P R R P R Y P G D D A S I E D L H A F W A A L W N Y L Y A V A
224A-1 G P R R P R C P G D D A S V E D L H E Y W A R L W N Y L Y A V A
224B-1 G P R R P R C P G D D A S I E D L H E F W A R L W N Y L Y A V A
224B-2 G P R R P R R P R Y P G D D A S I E D L H A F W A A L W N Y L Y A V A
225-1 G P R R P R Y P G D D A S I E D L H E Y W A R L W N Y L Y A V A
225-2 G P R R P R Y P G D D A S I E D L H A Y W A R L W N Y L Y A V A
225-3 G P R R P R Y P G D D A S I E D L H E Y W A R L W N Y L Y P V A
226-1 G P R R P R Y P G D D A S I E D L H E Y W A R L W N Y L Y A V A
226-2 G P R R P R C P G D D A S V E D L H E Y W A R L W N Y L Y A V A
226-3 G P R R P R Y P G D D A S V E D L H E Y W A R L W N Y L Y A V A
226-4 G P R R P R C P G D D A S I E D L H E F W A R L W N Y L Y A V A
226-5 G P R R P R C P G D D A S T E D L H A Y W A R L W N Y L Y A V A
226-6 G P R R P R C P G D D A S I E D L H E Y W A R L W N Y L Y A V A
226-7 G P R R P R C P G D D A S V E D L H E Y W A R L W N Y L Y A V A
226-8 G P R R P R C P G D D A S V E D L H E Y W A K L W N Y L Y A V A
Sequence 
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Chapter 3. RDA (Ras binding Dimeric aPP) peptides 
3-1. Structural analysis  
 
We decided to use the most dominant sequence from the evolution, 226-6, as well as 225-1 that 
has the same sequence except for cysteine at position 10 instead of tyrosine, for binding affinity 
studies and structural studies. The initial FP and pull-down experiments using 225-1 performed 
by John McGee verified that the peptides bind to Ras with mid-low nM affinity in vitro and also 
that they are capable of binding to endogenous Ras from cancer cell lysates and competing with 
Raf for Ras binding.  
 
For use in biochemical studies and structural studies, the hit peptides were prepared by bacterial 
expression, which was less time consuming and cheaper than SPPS. The following sequences 
were expressed and purified: 
 
RDA1: GSGGPRRPRCPGDDASIEDLHEYWARLWNYLYAVA (226-6) 
RDA2: GSGGPRRPRCPGDDASIEDLHEYWARLWNYLYRVA 
 
The peptides were named “Ras binding Dimeric aPP” (RDA) peptides, as the structures that 
were solved later showed that the high-affinity Ras-interacting species was a covalent dimer 
linked via the cysteines that arose at the 10th position during the directed evolution. The RDA2 
peptide is another hit peptide that was evolved in a yeast display experiment by John McGee to 
favor binding Ras-GTP over Ras-GDP. The GSG linker at the beginning of the sequences was 
put in order to facilitate proteolysis at the TEV site that comes directly before it.  
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Briefly, the RDA peptides were subcloned into a pET expression vector with an N-terminal His6 
tag followed by TEV cleavage site.  Then the construct was transformed into BL21 Rosetta cells, 
and the peptide expression was induced with IPTG. In order to increase the yield, molecular 
chaperone was co-expressed using an arabinose-inducible promoter. Afterward, the cells were 
harvested, lysed by sonication, and then the His6 tag was used to purify the peptides from the cell 
lysate using either Nickel or Cobalt immobilized metal affinity chromatography. Then the tag 
was cleaved off by TEV overnight. After TEV cleavage, the peptide was desalted and purified by 
reverse-phase HPLC, then lyophilized. As a final step, the peptides were dissolved in DMSO and 
quantified. FP experiments (Figure 43) showed that the Kd of the RDA peptides for K-Ras 
(G12V) are in low nM range (~8-17 nM). 
 
 
 
 
Figure 43. Fluorescence polarization (FP) measurements of the RDA peptides binding to K-Ras 
(G12V). The Kd for RDA1 for Ras is 17 nM with hill coefficient of 1.2, and the Kd of RDA2 is 8 nM 
with hill coefficient of 1.3. The FP experiment was conducted by John McGee.  
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The RDA peptides and K-Ras (G12) GppNHp complex was crystallized and the x-ray structure 
was solved by Dr. Matt Lee in the Verdine group. As expected, the overall structure shows that 
the RDA peptides bind to Ras in the region that overlaps with the effector domain (Figure 44), 
which explains the competition between Raf and the RDA peptides for the binding site in Ras 
from the yeast display experiments. While RalGDS or Raf interacts with mostly switch I region 
of Ras, the RDA peptides seem to bind to both switch I and switch II regions.  
 
Figure 44. K-Ras (G12V) GppNHp in complex with Ral GDS (PDB:1LFD) and RDA peptides. A: 
Ras protein (yellow) binding to its effector RalGDS (orange). B: Ras protein binding to RDA1 peptides. 
The RDA1 peptides are in a homodimeric form, the first monomer (pink) and the second monomer (blue) 
linked by covalent disulfide bond (represented in stick form) 
 
In addition, the peptides bind to Ras in a homodimeric form, covalently linked by a disulfide 
bond. This explains why the cysteines were continually found in position 10 during the directed 
evolution, as the covalent bond would stabilize the dimer and increase the affinity to Ras. The 
observation that the evolved RDA peptides dimerize is not entirely unexpected, as the original 
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aPP peptide that the RDA peptides are derived from have previously been reported to form head-
to-tail homodimers 91  and visualized as such in x-ray crystal structures 81 . 
 
Looking into the details of the structure, we can see that from the very first evolution round, the 
peptides have acquired residues that are important both for their binding to Ras as well as 
forming a stable dimer. The residue hits from the 221 library, His21, Asn29 and Tyr32 are 
important for binding to Ras while Trp24 and Trp28 are important for both binding to Ras and 
stabilizing the dimer via π stacking interactions. First of all, we see that the nitrogen atom in the 
imidazole of His21 from the first RDA monomer is forming salt bridges with the carboxylates of 
the Glu3 of Ras. In addition, the carbonyl group of His21 is also forming an indirect water 
mediated interaction with Glu3 of Ras (Figure 45). The imidazole group of His21 on the second 
monomer is also interacting with Ras, by forming hydrogen bonds with the OH groups of the 
side chains of Gln 70 and Tyr71 of Ras (Figure 46). The side chain of Asn 29 from the first 
RDA monomer forms hydrogen bonds with the carbonyl group of Ile55 of Ras and backbone 
amide nitrogen of Asp57(Figure 47). The backbone carbonyl from Tyr32 of the first RDA 
monomer interacts with guanidinium group of Arg68 of Ras, and OH group of the side chain of 
Tyr32 also indirectly interacts via water with carbonyl group of Ala59 of Ras (Figure 48).  
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Figure 45. His 21 of the RDA1 first monomer 
 
 
  
 
Figure 46. His21 of the RDA1 second monomer. 
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Figure 47. Asn29 of the RDA1 first monomer 	  
 
Figure 48. Tyr 32 of the RDA1 first monomer 
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The packing of the four tryptophan residues from the 24th and 28th positions in both monomers 
seems to contribute to the binding via hydrophobic interactions and also stabilizes the dimer by 
forming the core of the two peptides (Figure 49).  
 
 
Figure 49. Trytophan residues in the RDA peptides 
 
In hits from the 223 library, the hydroxyl group of serine side chain of Ser16 might be aiding in 
the stabilization of the monomer structure by forming a hydrogen bond with the NH group of 
Asp19, which is in i, i+3 position from it, and also by forming hydrogen bonds with the 
carboxylates of Asp19. These interactions are seen in both the first monomer and the second 
monomer, possibility contributing in helix stabilization (Figure 50). The carboxylates of Glu18 
from the first RDA monomer forms a salt bridge with the guanidinium sidechain of Arg41 from 
Ras (Figure 51). It was hard to tell from the structure why evolution favored Ala33, since it was 
neither binding to Ras or contributing to dimer stabilization. 
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Figure 50. Ser16 in RDA first (left) and second (right) monomer 
 
 
 
Figure 51. Glu18 of the RDA1 first monomer 
 
Throughout the evolutions, glutamate seemed to dominate over alanine in position 22, which 
might be due to its hydrogen bond interaction with OH group of Ser39 of Ras, as well as water-
mediated interaction with backbone amide nitrogen of Tyr40 of Ras (Figure 52). The position 26 
of RDA peptides was converged to arginine, the guanidinium of which seems to be forming a 
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salt bridge with carboxylate of Glu 37 of Ras and a hydrogen bond with the main chain carbonyl 
group of Asp 38 of Ras (Figure 53).  
 
 
Figure 52. Glu 22 of the RDA1 first monomer 
 
 
Figure 53. Arg 26 of RDA1 first monomer 
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As for the hits from the 224 library, both Cys10 and Tyr23 seem to be contributing to the dimer 
stabilization along with the tryptophan residues on the other side (Figure 54). The PRR 
extension that had emerged in the hits might also be due to the contribution to the stabilization of 
the structure rather than Ras binding, although the SAR for it was not investigated further.  
 
 
Figure 54. Tyr 23 and Cys 10 residues in the RDA1 peptides 
 
The structure of the RDA2 bound Ras complex showed that the arginine that was mutated from 
alanine in position 33 has water-mediated interaction with the γ-phosphate of the GTP analogue 
as well as an extra hydrogen bond with the backbone carbonyl group of Asp 57 or Ras (Figure 
55). This explains the higher affinity and selectivity for GTP-bound Ras over GDP-bound Ras of 
the RDA2 peptides.  
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Figure 55. Ala33Arg mutation in RDA2. Arginine interaction with gamma-phosphate of GTP analogue, 
GppNHP is shown. 
 
In summary, the residues that are important for binding and/or dimer interaction are highlighted 
as below.  
 
Table 10. Residues in RDA peptides that are important in binding to Ras and/or dimer 
stabilization. The residues important for Ras binding are highlighted in yellow, for dimer interaction in 
blue, and for both in magenta. 
 
 
3-2. Stabilization of state 1 in Ras by RDA peptides 
It has been shown previously that Ras in complex with GTP exists in dynamic equilibrium 
between two different conformations called state 1 and state 2 92,93 . In state 1, Ras adopts an 
inactive conformation with reduced binding to effectors, whereas in state 2 Ras adopts an active 
conformation. Effector binding is expected to shift the equilibrium toward state 2 92,94,95 . In state 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
1st-monomer G S G G P R R P R C P G D D A S I E D L H E Y W A R L W N Y L Y R V A
2nd-monomer G S G G P R R P R C P G D D A S I E D L H E Y W A R L W N Y L Y R V A
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2, Thr35 of switch I forms an interaction with the gamma phosphate of the GTP analogue, which 
closes the conformation and shields the GTP from the solvent 93 . In state 1, however, Thr35 
loses its contact with the gamma phosphate and switch I adopts an open structure revealing two 
surface pockets: the first one surrounded by two switch regions, and the second one by the 
switch I preceding residues and GppNHp 96 . (Figure 56) 
 
 
Figure 56. Wild type Ras in different states. A: Cartoon representation of Ras in state 2(left) and state 
1(right). The GppNHp is shown in ball and sticks model. Thr 35 has been colored in light pink, showing 
either the presence or absence of its interaction with the nucleotide phosphate. B: while Ras in state 
2(left)shows a closed conformation, the state 1(right) shows an open conformation, with two possible 
binding pockets. C: Pocket 1(left) shown in pink, pocket 2(right) shown in purple  (PDB: 4EFL for the 
state 1 Ras, 5P21 for state 2 Ras) 
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When we look at the structure of Ras that has RDA bound to it, we can see that the conformation 
is quite similar to the inactive conformation, state 1, in both the switch I and switch II regions. 
(Figure 57) Thr35, which is an indicator of the Ras state, also shows an absence of direct or 
indirect contact with the γ –phosphate.  
 
 
Figure 57. RDA bound Ras aligned with either state 2 Ras or state 1 Ras. The RDA bound Ras is 
colored in yellow, state 2 Ras in gray (left), and state 1 Ras in green (right). The primary helix of the 
RDA peptides is in light pink and the secondary helix in light blue. A & B:  Switch I region shows that 
the RDA bound Ras closely mimics the Ras in state 1, and the beginning of the beta strand residue 37-41 
is now in destabilized conformation. C&D: Switch II region shows that the RDA bound Ras is in close 
conformation with Ras in state 1. 	  
The RDA peptides that are bound to Ras are positioned along pocket 1, causing the switches to 
flip outward. (Figure 58) This observation suggests that state 1, which shows a previously 
unobserved binding pocket, has the potential to be used as a targetable structure in the design of 
Ras inhibitors. 
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Figure 58. RDA bound Ras. Ras is depicted in surface representation, and the RDA peptides in cartoon 
representation. The switch I region is in yellow, and switch II in green. We see here that with the binding 
of RDA peptides the switch region opens up, resembling the Ras state 1.  
 
As an extension of this idea, an FP experiment conducted by John McGee shows that the binding 
affinity of the 226-1 peptides toward K-Ras G12V  D38P double mutant improved to Kd of 14 
nM compared to 81 nM for K-Ras G12V (Figure 59). This D38P mutation was introduced in 
order to destabilize the conformation of the second beta strand of Ras, which normally resides 
from residue 38 to residue 46. In the RDA bound Ras, this second beta strand was pushed away 
losing half its secondary structure. In order to mimic this conformation, proline was introduced 
since it is known to disrupt secondary structures owing to restriction in its allowable dihedral 
angles and an inability to complete the H-bonding network.   
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Figure 59. FP measurement of 226-1 peptides binding to KRas G12V D38P double mutant.  
 
In order to confirm that the improved binding affinity came from Ras being stabilized in the 
conformation of the RDA bound form as we hypothesized, the RDAI bound Ras G12V, D38P 
double mutant complex was crystallized in the condition of 0.2-0.35M calcium chloride, 20-24% 
PEG 3350. A crystal that was formed under the condition of 21% (w/v) PEG 3350 and 0.25M 
calcium chloride using the hanging drop vapor diffusion method was soaked in cryoprotectant of 
0.3M calcium chloride, 22% PEG 3350 and 16% PEG 400 before being flash-frozen in liquid 
nitrogen for x-ray analysis. The crystal structure showed four molecules in the asymmetric unit 
in the space group of P 1 21 1, with a resolution of 1.91 Å and unit cell dimensions of a=40.55, 
b=232.5, c=48.21, α=90, β=90.16, γ=90. This structure was nearly identical with the RDAI 
bound Ras (G12V) complex. 
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Figure 60. RDAI bound Ras G12V D38P double mutant compared with RDAI bound Ras G12V 
mutant. 	  
We are currently in the process of crystallizing and solving the structures of the Ras G12V D38P 
double mutant to see if the introduction of proline also destabilizes the beta sheet formation in 
the absence of the RDA peptides. If the apo structure adopts an open state of Ras as we expect, 
we plan to use this mutant to screen for additional more Ras inhibitor candidates.  
 
3-3. i, i+4+4+4 stitched peptide  
There have been several attempts in the Verdine group to look at these promising Ras binders for 
activity in cells. However, they have shown poor results in cell-based activity assays, which 
might be attributable to the fact that the RDA peptides are approximately 70 amino acids and 
may be too large for adequate cell penetration. By analyzing the structure of the K-Ras/RDA1 
complex, we could see that all the residues that were interacting with the Ras protein seemed to 
be on the alpha-helices, with most of the interactions originating from the first helix. As expected, 
the polyproline helix seemed to be stabilizing the dimer. Therefore, we hypothesized that both 
the secondary alpha helix and the polyproline helix might be dispensable for interaction with Ras 
if we could stabilize the primary alpha-helix enough so that it could retain its structure 
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independently. We reasoned that this might help to enhance the cell permeability of the peptides 
while still retaining high-affinity binding to Ras.  
 
Previous RDA minimization efforts in the Verdine group involved strategies such as putting a 
staple on the helix of the monomer, linking the two helices at the termini, or forming a non-
covalent dimer of the two helices. However, none of these efforts gave promising results when 
the compounds were evaluated for binding to Ras. In an extension of this effort, I tried making a 
i, i+4+4+4 stitched peptides on both RDA1 and RDA2 peptides (Figure 61). Stitched peptides 
have been shown to give strong alpha helicity along with high thermal stability 97 , making this 
strategy appealing for the purposes of this project.  
 
 
Figure 61. Stitched RDA peptides. The RDA peptides have been truncated retaining only the primary 
alpha-helix, and the residues in green have been stitched in order to enforce the alpha-helicity.  
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The positions for non-natural amino acid incorporation were chosen in order to avoid the 
residues that were important for binding (Table 11).  
 
Table 11. Stitched RDA peptides. Stitched RDAI-1, 2 are based on RDA1 peptides, while stitched 
RDAII-1, 2 are based on RDA2 peptides that have A33R mutation. 
 
 
 
Upon metathesis of the substrate peptides shown in the table above, staples with S5-S5, R5-R5, 
and S5-S5 stereochemical combinations were expected for stitched RDAI-1 and stitched RDAII-
1, while R5-R5, S5-S5, and R5-R5 stereochemical combinations were expected for stitched 
RDAI-2 and stitched RDAII-2.  
 
The RCM reaction was performed for with 30 mole % GI catalyst twice for 2 hours, with each 
treatment utilizing a freshly prepared solution in dichloroethane. Here we observed efficient 
RCM by almost 100% product conversion after only one 2 hour treatment (Figure 62). The 
single product peak showed a decrease in mass of 84 relative to the starting material, as expected 
from the loss of ethylenes from the metathesis reactions.  
 
  
 
Peptide
Stitched RDAI-1 I E S5 L H E B5 W A R B5 W N Y S5 Y A V A
Stitched RDAI-2 I E R5 L H E B5 W A R B5 W N Y R5 Y A V A
Stitched RDAII-1 I E S5 L H E B5 W A R B5 W N Y S5 Y R V A
Stitched RDAII-2 I E R5 L H E B5 W A R B5 W N Y R5 Y R V A
Sequence
	  	   87	  
 
Figure 62. Stitched RDA peptides. 10% acetonitrile (0min) -100% acetonitirile (20min) run in LC/MS 
 
However, the products had low solubility in water or buffer, as could be predicted from the 
observation that their LC/MS retention times corresponded to very high percentages of 
acetonitrile.  In addition, the stitched peptides did not show detectable binding to Ras up to 10 
uM in a fluorescence polarization binding experiment and had only moderate helical content 
(40~55 % helicity) when analyzed by circular dichroism. These experimental results suggest that 
the polyproline helix might be more crucial for structural stabilization than we assumed.  
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Chapter 4. Heterodimeric Ras inhibitor  
4-1. Homodimer vs. heterodimer 
The RDA peptides are a symmetrical dimer, but it is apparent in the co-crystal structures 
described above that rarely do residues from both monomers interact with Ras.  In reality, for the 
most part only residues from the primary helix seem to be involved in the binding. Therefore, 
although the RDA peptides are symmetrical in structure, they interact asymmetrically with Ras. 
This suggests that there is an opportunity to optimize the dimer for interaction with Ras if we can 
break its symmetry. Essentially, the residue at a given position on one monomer might not be 
optimal for the corresponding position on the other monomer, and the more favorable amino acid 
mutation might be suppressed if the corresponding residue from the other monomer is not 
compatible with it.  
 
It has been shown that two different proteins can be expressed from a single yeast display vector 
using a separate promoter and that the heterodimer can be stabilized through disulfide bonds 98 . 
Furthermore, by using the yeast Gal 1-10 bidirectional promoter, it is possible to express two 
open reading frames from one plasmid by galactose-induction 99 . This bidirectional Gal 1-10 
promoter enables simultaneous expression of two different genes, providing the opportunity to 
evolve heterodimeric RDA peptides.  
 
Our idea was to fuse one monomer with Aga2p to be anchored on the yeast cell surface 
(anchored peptide), and another monomer to be produced as a soluble fragment (free peptide). 
These peptides were coexpressed in the yeast cells for yeast display experiment. In order to 
ensure selecting for heterodimer over homodimer, we planned to modify the anchored peptide 
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such that it would not bind to Ras as a homodimer. Thus, the homodimers of the anchored 
peptide on the cell surface would not be able to bind to Ras, while the homodimer of the free 
peptide would not be screened by FACS since it would not be attached to the cells anymore. 
Therefore, the discovery of hits would depend on two steps: (1) the heterodimer formation of the 
anchored peptide with the free peptide and (2) recognition of Ras by the heterodimer.  
 
In pursuit of this idea, Dr. John McGee from the Verdine group performed a yeast display 
experiment using the dual promoter system to express the two peptides simultaneously. The 
construct was designed with mutations in the non-binding anchored peptide in positions 25, 29 
and 32, in order to disrupt binding to Ras. The A25N mutation would give a steric bump, while 
N29A and Y32A were intended to abrogate the binding by loss of important interaction between 
the peptides and Ras. In addition, in order to aid the dimerization of the two different peptides, 
Ile17 on the primary helix and Val34 on the secondary helix were mutated to form a putative 
bump-hole (Table 12).   
 
Table 12. Initial template design for the heterodimeric RDA peptides. The blue residues are 
mutations introduced to disrupt binding to Ras, and the green residues are put in for putative bump-hole.  
 
 
 
Using this design, we wanted to achieve two goals by evolving a heterodimer RDA: improving 
binding affinity and enhancing cell permeability.  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Free.peptide.......
(1st.monomer)
G S G G P R R P R C P G D D A S X E D L H E Y W A R L W N Y L Y R V A
Anchored.peptide.
(2nd.monomer)
G S G G P R R P R C P G D D A S I E D L H E Y W N R L W A Y L A R X A
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In the library designed to achieve improvement in affinity of the peptide to Ras, the C-terminus 
of the primary helix was mutated and elongated by one more residue to form another interaction 
with Ras. As for the secondary helix, mutations were introduced into positions 21, 25 and 28, 
which appear to face Ras in the crystal structures of the RDA homodimers (Table 13).  
 
Table 13. Library design to achieve improvement in affinity of the Ras binding peptides 
 
 
 
For improvement in cell permeability, anionic residues such as glutamates or aspartates were 
removed, avoiding those that seemed important for either binding to Ras or dimer formation. In 
this library, positions 14 and 19 of the primary helix and positions 14, 18, 19 of the secondary 
helix were mutated (Table 14).  
 
Table 14. Library design to achieve improvement in cell-permeability of the Ras binding peptides 
 
 
 
The directed evolution results from the libraries showed us that for the bump-hole mutation, 
leucine was strongly favored in position 17 of the primary helix, while for its pair either valine or 
phenylalanine was selected. For the affinity mutations, it did not seem like there was a 
preference for specific amino acids for c-terminal residues in the primary helix, but in the 
secondary helix, histidine was favored over tyrosine at position 21, and glutamine was favored at 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Free.peptide.......
(1st.monomer)
G S G G P R R P R C P G D D A S X E D L H E Y W A R L W N Y L Y R V X X
Anchored.peptide.
(2nd.monomer)
G S G G P R R P R C P G D D A S I E D L X E Y W X R L X A Y L A R X A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Free.peptide.......
(1st.monomer)
G S G G P R R P R C P G D X A S X E X L H E Y W A R L W N Y L Y R V A
Anchored.peptide.
(2nd.monomer)
G S G G P R R P R C P G D X A S I X X L H A Y W N R L W A Y L A R X A
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position 25. Interestingly, Tyrosine seemed to be favored over the tryptophan that originally 
occupied position 28. Lastly, for surface charge mutations, Gln, Asn or Lys replaced the anionic 
residues in the parent peptide, shifting the overall charge of the peptide from -2 to +5. This 
increase in the formal charge was expected to be helpful in enhancing cell permeability. The 
results from the two libraries were combined and the resulting heterodimer was named 24G 
(Table 15), which proved to be a ~20 pM binder to Ras according to the surface plasmon 
resonance assays performed by John McGee.  
 
Table 15. 24G peptide sequence. Residues from evolution for improved affinity are in red, for improved 
cell permeability in blue, and for putative bump-hole are in green.  
 
 
 
Another heterodimer pair based on 24G peptide template was evolved in a yeast display 
experiment using 100 nM Ras in order to focus on forming a stronger heterodimer. Leu20 of the 
primary helix was mutated to either tyrosine or phenylalanine, and the residues on the secondary 
helix that would be surrounding them were mutated so that the amino acid combination that best 
accommodates the designed bump would be evolved. The hit heterodimer from this round of 
evolution was named the 32P peptide (Table 16).  
 
24G$Peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
1st$monomer S G P R R P R C P G D Q A S L E E L H E Y W A R L W N Y L Y R V A H
2nd$monomer G G G P R R P R C P G D N A S I K Q L H A Y W Q R L Y A Y L A A V A
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Table 16. Library design and the resulting 32P peptide sequence 
 
 
 
4-2. X-ray crystallization studies 
 
In order to investigate how the 24G peptide gained stronger affinity toward Ras, we proceeded to 
form a complex between this peptide and Ras and undertake crystallization trials for x-ray 
structural studies.  
 
 
Figure 63. SDS-PAGE of 24G dimer, Ras, and the Ras/24G complex 
 
We separately expressed Ras and the 24G peptide in bacteria.  For the 24G peptide, we opted to 
introduce selenocysteine at the positions occupied by cysteine, expecting that this would provide 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Free.peptide.......
(1st.monomer)
S G P R R P R C P G D Q A S X E E Y/F H E X W A R L W N Y L Y R V A H
Anchored.peptide.
(2nd.monomer)
G G G P R R P R C P G D N A S I K Q L H A X W Q R X Y A X L A A V A
!
32P.Peptide 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
1st.monomer S G P R R P R C P G D Q A S N E E Y/F H E Y W A R L W N Y L Y R V A H
2nd.monomer G G G P R R P R C P G D N A S I K Q L H A F W Q R L Y A F L A A V A
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a non-reducible variant that would simplify the complex formation. After incubating Ras and the 
24G peptide for ~2 hours (Figure 63), the complex was purified by gel filtration and 
subsequently screened initially against  ~500 crystallization conditions. We analyzed the initial 
crystal hits under UV light to confirm the existence of peptide, as the peptides have three 
tryptophan residues in the sequences whereas Ras has none. For the crystals that glowed under 
UV, we expanded and optimized the crystallization conditions to get bigger and higher quality 
crystals. One of the conditions that was expanded and eventually yielded a crystal that diffracted 
upon x-ray irradiation was from the screening solution of 0.2M ammonium sulfate, 0.1 M 
HEPES pH 7.5, 25% (w/v) PEG 3350. In the expansion trays, reservoir solution in the range of 
0.15M-0.25M ammonium sulfate, 0.1 M HEPES pH 7.5, 23-27% PEG solution was screened by 
mixing 0.5 ul of the reservoir solution with 0.5 ul of 0.44 mM K-Ras/24G complex (11.9 mg/ml 
in solution of 20 mM Tris pH 7.0, 50 mM NaCl, 5 mM MgCl2) at 20°C in hanging drop vapor 
diffusion method. The crystal that grew under the condition of 0.2M ammonium sulfate, 26% 
PEG 3350, 0.1M HEPES pH 7.5 was picked and soaked in a cryoprotectant solution containing 
0.2 M ammonium sulfate, 26% PEG 3350, 0.1M HEPES pH 7.5, and 14 % PEG 400 just before 
flash-freezing the crystal in liquid nitrogen. In the crystal structure, there were two molecules in 
the asymmetric unit with  a space group of P 1 21 1 and  unit cell dimensions of a=38.079, 
b=82.900, c=70.416, α=90, β=104.65, and γ = 90. The resolution was 2.57 Å, so we optimized 
the condition further by varying the ratio of the protein and the reservoir solution in the 
crystallization drops. The crystal that grew with the ratio of 2:3 (0.33 ul protein: 0.5 ul reservoir 
solution) in the same reservoir solution diffracted even better, producing a 1.72 Å dataset in the 
same space group (P 1 21 1) with unit cell dimensions of a=38.15, b=86.84, c=71.04, α=90, 
β=103.6, and γ = 90.  
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Figure 64. Crystallization conditions for 24G bound K-Ras (G12V) GppNHp complex 
 
In the structure of the 24G peptide bound to K-Ras (G12V), we observed new interactions 
between Ras and the secondary helix. (Figure 65) As shown in the previous RDA bound K-Ras 
(G12V) complex, the imidazole group of His21 forms hydrogen bonds with side chains of Gln70 
and Tyr71 of Ras, which explains why the evolution favored histidine. The newly evolved 
residue Gln25 was observed to form a direct hydrogen bond with Gln70 of Ras, and the newly 
evolved Tyr28 indirectly interacts with the backbone of Thr74 of Ras via an intermediary water 
molecule and might be having van der waals interaction with side chain of Lys5 of Ras. These 
mutations overall seem to help the peptide dimer to bind even more strongly to Ras protein by 
positioning the secondary helix toward the switch II region of Ras, explaining the improved Kd 
measured in the biochemical assay.  
	  	   95	  
 
Figure 65. Analysis of the 24G/K-Ras complex. On the left shows the 24G/K-Ras complex overlaid 
with RDAI/K-Ras complex(gray). On the right shows the interactions from the second monomer of the 
24G peptides with Ras.  
 
In initial screening for crystallization of the 32P/Ras complex, the drop mixture of 0.5 ul of 0.37 
mM K-Ras/32P complex(10.0 mg/ml in solution of 20 mM Tris pH 7.0, 50 mM NaCl, 5 mM 
MgCl2) with 0.5 ul of 0.15-0.25 M ammonium formate, 18-21% PEG3350 yielded small, grain-
like crystals. Unfortunately the crystals did not diffract at all, and varying the ratio of the drop 
mixture of the reservoir condition did not seem to help. Looking back at the 24G/Ras complex in 
the same conditions, we see that in the initial screen the crystals were also very small and took a 
few days to grow. However, in the larger scale screening, the complex yielded a bigger crystal 
that diffracted to a 1.98 Å resolution. Since there are only a few residues mutated in the 32P 
peptide compared to 24G peptide, and since the overall surface and the backbone should be 
similar, we expected the crystal packing to be similar as well. Therefore, we decided to try 
heteroseeding the crystals from 24G/Ras complex to grow 32P/Ras complex crystals (Figure 66). 
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The K-Ras/32P crystals began to grow within a few hours once the drop was heteroseeded with 
24G/K-Ras complex crystals (Figure 67). A crystal was picked from 0.25M ammonium formate, 
15% PEG 3350 condition, and was soaked in the reservoir solution supplemented with 20% 
glycerol prior to being flash frozen in liquid nitrogen. The structure was determined to be in the 
space group of P 21 21 21, unit cell dimension of a=70.97, b=73.22, c=81.04, α=90, β=90, γ = 90, 
with a 1.92 Å resolution. 
 
Figure 66. Comparison of the 24G/K-Ras and 32P/K-Ras crystals in the same condition 
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Figure 67. Heteroseeding. The crystals of the 32P-Ras complex began to grow when heteroseeded with 
the 24G-Ras microcrystals.  
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In the overall crystal structures of 24G and 32P bound to Ras, the peptides look quite similar to 
each other (Figure 68). When we look at the residues that were evolved via the yeast display 
experiment, compared to the ones in 24G those in 32P seem to be engaged in more 
intermonomer packing (Table 17). This suggests that the heterodimers might be packing better 
against each other, although it is hard tell for sure without direct comparison of the 
corresponding homodimer structures. 
 
Table 17. Residue interactions in 32P and 24G peptides 
 
 
32P Peptide 
residues
Residues from the 
other helix within 4Å
24G Peptide 
residues
Residues from the 
other helix within 4Å
1st Asn17 Phe30 Leu17 Tyr30
Phe20 Phe23, Leu27 Leu20 Tyr30
Tyr23 Phe23, Leu27 Tyr23 Tyr23, Leu27
2nd Phe23 Phe20, Tyr23 Tyr23 Tyr23
Leu27 Phe20, Tyr23 Leu27 Tyr23
Phe30 Asn17 Tyr30 Leu17, Leu20
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Figure 68. Comparison of 32P (yellow) and 24G (gray) peptide 
 
Chapter 4. Conclusions and future directions 
In part II of this thesis, we have shown to evolve peptide binders to Ras, which was previously 
thought to be one of the most intractable targets. With the difficulty of using rational design in 
the beginning, we have started with a naïve screening of a libraries of a number of peptide 
scaffolds, one of which eventually yielded peptide binders to Ras with Kd  of low-mid nM. By 
solving the structure of the hit peptides bound to Ras and analyzing it, we were able to further 
optimize the peptides for improved affinity. The initial homodimer binders were evolved to a 
heterodimer binders, which yielded even higher affinity to Ras from having extra contact 
residues in the secondary monomer that were previously not possible due to the constraints 
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associated with the symmetry of the homodimer. The binding of the hit peptides to Ras was 
assessed in a number of biochemical experiments such as fluorescence polarization, surface 
plasmon resonance (biacore) and immunoprecipitation of cancer cell lysates. Currently in 
Verdine group we are trying to improve the cell permeability as well as endosomal escape of the 
peptides by optimizing the sequence. 
The crystal structures of the hit peptides bound to Ras suggest that the peptides might be 
stabilizing state 1 conformation of Ras, which is a weak binding state for effectors. The fact that 
Ras exists in a dynamic equilibrium between these different states, where one of which would 
abrogate the binding of effector to Ras, gave us a new targeting strategy. By fixing the 
equilibrium to state 1 by introducing mutation into Ras, we speculate that we might be able to 
screen for more potential inhibitors that would fit into the binding pockets that exist in that 
particular state.  
 
Chapter 5. Experimental Method 
5-1. Yeast passage 
Typically yeast cell was passaged using SDCAA media a day before, and then induced with 
SGCAA media 20-24 hours prior to sorting. For antibiotics Kanamycin and ampicillin was used.  
 
• SDCAA Media: 8.56 g of sodium phosphate monobasic (NaH2PO4H2O), 5.4 g of sodium 
phosphate dibasic (Na2HPO4), 20 g of 20 g dextrose, 6.7 g of Difco yeast nitrogen base, 5 g 
of bacto casamino acids were dissolved and mixed well in 1000 ml of deionized H2O, and 
filter sterilized. 
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• SGCAA Media: 8.56 g of sodium phosphate monobasic (NaH2PO4H2O), 5.4 g of sodium 
phosphate dibasic (Na2HPO4), 20 g of 20 g galactose, 6.7 g of Difco yeast nitrogen base, 5 g 
of bacto casamino acids were dissolved and mixed well in 1000 ml of deionized H2O, and 
filter sterilized. 
 
5-2. MACS  
A day after the induction, the density of the yeast was measured by OD600.  Generally absorbance 
of 1 indicates about 107 cells/ml. For MACS experiment, typically 1 or 2x109 cells were 
collected and pelleted. The pellet was washed and resuspended with MACS buffer to the final 
binding volume. In the cold room, labeled K-Ras G12V mutant protein was added to a desired 
binding concentration, and incubated for about 30-60 minutes at room temperature. The sample 
was then washed and pelleted with MACS buffer, and either streptavidin beads or anti-biotin 
beads were put and incubated for 10-30 minutes. Afterward, autoMACS machine was used to 
collect the labeled cells. The collected cells were grown in SDCAA media with Kan/Amp 
antibiotics at 30 oC. The number of the sorted cells was determined by plating and counting the 
colonies. (a colony represents ~16,000 eluted cells)  
 
• MACS buffer: 150 mM NaCl, 5mM KCl, 15 mM sodium phosphate, 0.5 % (w/v) BSA,  
5mM MgCl2, adjusted to pH 7.4~7.5 
	  	   102	  
 
5-3. FACS  
After about 20 hours of induction, desired amount of cells were washed, pelleted and 
resuspended with FACS buffer to the final binding volume. Labeled K-Ras G12V mutant protein 
was added, pelleted and resuspended with either Alexa 488 labeled anti-HA antibody or FITC-
labeled anti-FLAG antibody and SA-APC or NA-PE to the appropriate labeling volume and 
incubated at 4 oC for 10 minutes, protected from light. SA-APC and NA-PE was alternated to 
prevent enrichment of secondary binder. The labeled cells were once again washed and pelleted, 
and resuspended in FACS buffer immediately prior to sorting. The sorting was done using the 
FACS machine at the Bauer core at Harvard University.  
 
• FACS buffer: 150 mM NaCl, 5mM KCl, 15 mM sodium phosphate, 0.1 % (w/v) BSA,  
5mM MgCl2, adjusted to pH 7.4~7.5 
 
5-4. Hit sequencing 
After sorting, the enriched cells were passaged overnight, and mechanically lysed, and then 
Qiagen miniprep kit was used to acquire the plasmid DNA.  The yeast display vector was then 
transformed into bacteria (XL-10 gold cells) for colony PCR. The PCR product was used for 
sequencing the hits and to use them as templates for error-prone PCR to prepare new yeast 
display library for directed evolution screening. 
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5-5. Yeast transformation 
S. cerevisiae strain EBY100 was streaked on a YPD plate and grown for 2-3days at 30 oC. The 
evening before transformation, a single colony was picked and inoculated in YPD media, and 
was shaken overnight. Then 110 ml of pre-warmed YPD to an OD600 of 0.1 was inoculated and 
shaken until the OD600 reached 1.40. Then, 1.0 ml of Tris-DTT was added and continued to 
shake for exactly 15 minutes. The cells were then pelleted, washed and resuspended in cold E 
buffer. 
 
To prepare the DNA for transformation, appropriate amount of digested and purified pCTCON2 
vector was mixed with appropriate amount of DNA insert (typically 1:4 ratio was used). The 
mixture was precipitated using PelletPaint. After thoroughly drying the pellet, it was redissolved 
in milliQ water and kept at 4 oC until transformation.  
 
Appropriate amount of cells were mixed with the DNA and incubated for 10 minutes, and 
electroporation was performed for transformation at 0.54kV, 25 µF in a genePulser II 
electroporator. Afterward, they were shaken in YPD media for 1 hour at 30 oC, pelleted and 
resuspended in SDCAA media with kanamycin and ampicillin antibiotics. A small portion of the 
cell suspension was taken out and plated to determine the transformation efficiency and the 
library size.  
 
• YPD media: 20g of dextrose, 20 g of bacto peptone, and 10 g of bactoyeast extract, 
mixed into 1000 ml deionized water and sterilized by filtration 
• Tris-DTT: 2.5M DTT in 1M Tris pH 8.0  
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• E-Buffer: 10 mM Tris, 270 mM sucrose, 1mM MgCl2, pH 7.5 
 
5-6. RDA peptides expression and purification 
Peptide expression (for RDA1 and RDA2 peptides) 
RDA1 : GSGGPRRPRCPGDDASIEDLHEYWARLWNYLYAVA (Dimer) 
RDA2 : GSGGPRRPRCPGDDASIEDLHEYWARLWNYLYRVA (Dimer) 
A small amount of RDA peptide transformed BL21 cells were scraped into LB media with 
Kanamycin and Ampicillin antibiotics and shaken at 37 oC overnight. The next day the overnight 
culture was distributed equally to twelve 1L of LB media with Kanamycin and Ampicillin 
antibiotics. The cells were shaken at 37 oC, 215 rpm until they reached an OD600 of 0.7, which 
typically takes around 5-7 hours. Once the cells reached the OD, 500 mM IPTG and 2 ml of 10% 
w/v arabinose was added to each 1L flask, and were shaken for 4-5 more hours at 30 oC. Note 
that arabinose was used here for the induction of dnaK, dnaJ, grpE, GroEL, and GroES 
chaperones to aid the expression of the peptides. Afterward the cells were pelleted for 20 minutes 
at 4200 rpm, and the media was poured off. About 40 ml of His buffer 1S was used to resuspend 
the pellet of 2L amount of cell culture, and the mixture was snap-frozen in liquid nitrogen for 
several minutes, and stored at -80 oC.  
 
• His Buffer 1S: 50 mM sodium phosphate pH ~7.5, 1000 mM NaCl, 10 mM imidazole 
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Peptide purification 
The pellets were thawed and one tablet of EDTA-free protease inhibitor was mixed per 4 liters of 
culture. The cells were sonicated with a tip sonicator using 6 cycles of 10 s on, 15 s off at 6.5 
power level. Once finished, the lysate was centrifuged at 15,000 rpm for 35 minutes in the high-
speed centrifuge. After the centrifuge is done, decant and filter the supernatant through 1.2 um 
membrane, and then mixed and incubated with cobalt resin for 30-40 minutes. Typically ~2ml 
bed volume of cobalt resin was used per 2 liters of culture. Afterward, the flow-through was 
drained, and then the column was washed with His Buffer 1S. Then Hisbuffer 2S was used to 
elute the protein. The existence of protein in the eluted buffer was verified by adding 5 ul of 
liquid from the column tip to 95 ul Bradford reagent. EDTA was added to the final concentration 
of 0.5 mM to the eluate, and then the sample was transferred to a centriprep YM-3 and 
centrifuged at 3200 rpm until it concentrated down to about 2ml per 2 liters of cell culture. Once 
the eluate has finished concentrating, it was filtered through 0.45 um Tuffryn membrane and 
buffer exchanged into TEV cleavage buffer using a pair of tandem 5 ml HiTrap desalting 
columns. The peptide fractions were collected, with care not to include the salt peak (Figure 69).  
TEV was added to the sample, and the cleavage reaction went overnight at room temperature. 
Three connected C-18 sep-pak columns were used to desalt the solution, and the peptide was 
purified by HPLC (Figure 70). The collected peptides went through speed vac to evaporate the 
acetonitrile, then lyophilized.  
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Figure 69. FPLC for buffer exchange of the peptides for TEV cleavage. The peak at ~4 min shows the 
peptide peak, while the peak at ~10 min shows salt peak.  
 
 
Figure 70. After purification of the RDA peptides by HPLC. The first column shows the UV 
spectrum, and the second column the mass spectrum.  
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5-7. Heterodimer peptides expression and purification 
Peptide expression (for 24G and 32P peptides) 
24 peptide: SGPRRPRSePGDQASLEELHEYWARLWNYLYRVAH 
G peptide: GGGPRRPRSePGDNASIKQLHAYWQRLYAYLAAVA 
32 peptide: SGPRRPRSePGDQASLEELHEYWARLWNYLYRVAH 
P peptide: GGGPRRPRSePGDNASIKQLHAYWQRLYAYLAAVA 
Note that in these peptides we have incorporated selenylcysteines (SeCys) instead of cysteines. 
The constructs are in Cys auxotrophic E. coli cell line BL21 CysE. The cells were grown 
overnight in LB media, supplemented with Kanamycin, Carbenicillin and cysteines. The next 
day the cells were pelleted and resuspended and grown in two flasks of 500 ml DLMM media as 
previously described 100,101 , with Kanamycin, carbenicillin and cysteines added. The cells were 
shaken at 37 oC, 215 rpm until they reached an OD600 of ~2.2, and then induced with 200 mM 
IPTG and shaken for 15 more minutes. Afterward, the cells were pelleted and resuspended in a 
second batch of DLMM with IPTG and selenylcysteines. The cells were grown overnight at 25 
oC. The next day, I pelleted the cells and froze them slowly at -80 oC.  
Peptide purification (for 24G and 32P peptides) 
The pellets were slowly thawed, and then ~25 ml Lysis buffer B-
Per+lysozyme(3mg/50ml)+universal nuclease for cell lysis was used to resuspend each pellet 
from ~500 ml media. After rocking the solution for ~10 min at room temperature, salt was put to 
a final concentration of 500 mM, and imidazole to ~10 mM. (For 25 ml, 2.5 ml of 5 M NaCl was 
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used, and 0.125 ml of 2 M imidazole was used) After rocking for 5 more minutes, the solution 
was centrifuged for ~25 min at ~15,000 rpm. About 2 ml bed volume of cobalt resin was 
prepared for each column. They were washed with milliQ water and His Buffer 1S. After the 
centrifuge, the lysate was clarified through 1.2 um membrane into the column, and they were 
mixed with the resin for 15-30 minutes. Afterward, the lysate was drained through the column by 
gravity, and then column was rinsed with His Buffer 1S until the color of the Bradford reagent 
didn’t turn blue with the solution coming out from the column (95 ul of Bradford reagent+ 5ul of 
sample). Then Hisbuffer2S was addedto elute the protein, and EDTA was added to the eluate to 
the final concentration of 0.5 mM. It was transferred to a centriprep YM-3 and centrifuged at 
3200 rpm until it concentrated down to 2~4 ml. The concentrated eluate was filtered through 
0.45 um Tuffryn membrane and buffer exchanged into TEV cleavage buffer using a pair of 
HiTrap Columns. TEV was added to cleave the peptides overnight at room temperature. After 
overnight TEV cleavage, the peptides were desalted using sep-pak column, eluting at 75 
acetonitrile in water, 0.1% TFA. Afterward the heterodimer peak was purified by HPLC (Figure 
71) and lyophilized.  
	  	   109	  
 
 
Figure 71. After HPLC purification of the heterodimer 
 
5-8. Ras protein transformation, expression & purification  
 
Ras protein Transformation 
Verdine group plasmid stock 2638 (pET28b, human k-ras G12V core domain, hexahistidine 
tag+GGGG) was transformed into BL21 DE3 cells for expression of recombinant G12V k-Ras 
protein. . ~1 ul of the plasmid was mixed into competent cells taken out from -80 oC stock, and 
let it sit for ice for 30 minutes. The sample was heat shocked for 45 seconds at 42 oC, and then 
rested on ice for 2 min. Under sterile technique, 500 ul of SOC media was put in and incubated 
in the shaker for 1 hour at 37 oC. Afterward, ~6 ml of LB media with Kanamycin antibiotic was 
put in and incubated at 37 oC overnight.  
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The next day, for transformed BL21 DE3 cells, the cells were pelleted and then resuspended in 
LB media with 15% glycerol. They were then snap-frozen in -80 oC.  
 
Ras protein expression 
For expression, some cells from the K-Ras transformed cell stock was scarped out, and they were 
grown overnight in LB media with Kanamycin and chloramphenicol as antibiotics. The next day, 
they were equally distributed into twelve 1-L cell flasks, and grown until they reached the OD of 
~1.0, and then 1 mM IPTG was put in for induction. Afterward, they were grown at 30 oC 
overnight (12~16 hours). The next day, the cells were pelleted 2L each, resuspended in Ras lysis 
buffer, snap-frozen and stored in -80 oC.  
 
• Ras Lysis: 20 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole 
 
Ras protein purification 
A 2L cell pellet from -80 oC freezer was taken out and thawed. Then it was sonicated (3 min, 3 
sec on, 8 sec off, 6.5) and ultracentrifuged for 20 minutes. The cell lysate was incubated with ~5 
ml regenerated Ni resin for about 30 min. After the incubation the column was washed with 
~70ml buffer and then the protein was eluted using ~30 ml elution buffer. I adjusted the amount 
of buffer needed by checking the presence or absence of protein using 5 ul of the eluant with 95 
ul Bradford reagent. The eluate was concentrated to about ~2 ml, and then buffer exchanged to 
TEV protease cleavage buffer using 2 tandem 5ml HiTrap desalting columns. The collected 
fractions were pooled and ~1mg of TEV was added at 4 oC, overnight (Figure 72). The next 
morning the tagless protein was concentrated down to less than 2ml, and then buffer exchanged 
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into Goode Exchange buffer. The correct fractions were collected and concentrated down to less 
than 2ml. Noticeably the sample that was yellow to brownish color are shown to be transparent 
in this step. For nucleotide exchange, 4X of the desired nucleotide (GMP-PNP) along with CIP 
at ~2.5U/mg protein was added to the sample at room temperature for 1 hour. After the exchange, 
the sample was spinned down and the supernatant buffer exchanged into Ras GF buffer using 
Superdex 200 Prep column. The fractions containing the Ras protein was collected and 
concentrated to a desired concentration, then saved in -80 oC.   
 
 
• Ni-NTA Elution buffer: 20 mM Tris pH 8.0, 300 mM NaCl, 250 mM imidazole 
• TEV protease cleavage buffer: 20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT 
• Goode exchange buffer: 32 mM Tris pH 8.0, 200 mM NH4SO4 
• Ras GF Buffer: 20 mM Tris pH 8.0, 50 mM NaCl, 5 mM MgCl2 
 
 
 
Figure 72. SDS-PAGE analysis of Ras TEV cleavage. 1: ladder, 2: Ras before TEV cleavage, 3: Ras 
after TEV cleavage 
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Ras Nucleotide loading check 
~2nmol of Ras proteins were raised to 150 ul with ultrapure water, and then mixed with 150 ul of 
Nucleotide loading buffer. The nucleotide loading was checked by analyzing the sample by 
reverse-phase HPLC using a 20 minutes isocratic run in Nucleotide loading buffer for HPLC. 
The elution time was compared with those of GMPPNP and GDP. (Figure 73) 
 
• Nucleotide loading buffer: 100 mM Potassium phosphate pH 6.5, 10 mM 
tetrabutylammonium bromide 
• Nucleotide loading buffer for HPLC: 100 mM Potassium phosphate pH 6.5, 10 mM 
tetrabutylammonium bromide, 7.5% acetonitrile 
 
 
Figure 73 Elution time for GDP (1st column), GMPPNP (2nd column) and nucleotide loaded on Ras 
(3rd column). Here the elution time for Ras nucleotide matches that of the GMP-PNP 
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5-9. X-ray crystallography studies of the Ras/peptide complex  
 
Complex Formation 
Lyophilized peptides (RDA1, RDA2, 24G and 32P) were dissolved in DMSO and quantified, 
and were made to a starting concentration of 1 mM in DMSO. 100 nmol of peptides and Ras 
protein were diluted in ~5ml Ras buffer each. Then they were gradually mixed together. The 
mixture was incubated at 4oC for 2 hours. Then it was centrifuged for 5 min at 4500 g, and the 
supernatant was concentrated down to 2 mL for purification by gel filtration using superdex 75 
column. The fractions for the peak of the complex was pooled and concentrated.  
 
• Ras buffer: 20 mM Bis-Tris pH 7.0, 50 mM NaCl, 5 mM MgCl2  
 
Crystal condition screening and X-ray diffraction 
Typically, initial screens were conducted using 5 different kinds of commercially available 96 
reagent crystallization screen kits: Crystal Screen 1, Crystal Screen 2, JCSG+ Suite, PEGs Suite, 
PEGs II Suite, Index screen. 96-well plates in a sitting drop vapor diffusion were used, and 
crystallization drops were made by mixing 0.2 ul complex with 0.2 ul of the screening solution. 
The crystals that grew were checked with UV images to see if they contain the peptides. While 
the peptides have tryptophan fluorescence while Ras proteins do not have any tryptophan 
residues that would glow in UV. This helps to exclude salt crystals or only Ras protein crystals. 
Afterward, the conditions that gave the crystals were expanded and optimized using 0.5 ul of 
peptides mixed with 0.5 ul of the screening solution, or with varying ratios, using the hanging 
drop vapor diffusion method at 20 oC.  
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For heteroseeding, first the K-Ras/24G crystals were collected using a loop, and were washed 
using the reservoir solution a few times. They were transferred to fresh drops 2-3 times for the 
washing. Then ~50 ul of drops containing the crystals were collected into the sead bead 
tube(Hampton Research) which was pre-chilled on a bucket of ice. The seed bead tube was 
vortexed for three minutes, stopping every 30 seconds to cool the tube on ice. The seed stock 
was diluted 10 fold and 100 fold to determine the optimal seeding concentration. 0.5 ul of seed 
stock was mixed into the K-Ras/32P crystallizaion drops that were equilibrated in advance for a 
day. The remaining crystal seed stocks were snap frozen in liquid nitrogen and saved in -80 oC 
freezer.  
 
X-ray diffraction data were collected at the beamline of the Argonne Photon Source. HKL2000 
program suites were used to process all diffraction data. The structures were determined by 
molecular replacement with Phaser either using the previously determined K-Ras structure (PDB 
3GFT) or K-Ras/RDA1 complex complex that was solved as a search model. The structure was 
refined using COOT and  Phenix Refinement.  
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